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Abstract 
Due to their capacity of silencing single genes sequence-specificly, antisense 
oligonucleotides (ASOs) and small interfering RNAs (siRNAs) represent two 
promising strategies in the development of urgently needed specific and safe 
therapies. Off-target effects, however, are among the major hurdles for their clinical 
success. A DIGE-based proteomic approach (two-dimensional gel electrophoresis in 
combination with mass spectrometry) comparing the phosphorothioate antisense 
oligonucleotide Oblimersen (Genasense, G3139) to a bcl-2-targeted siRNA 
sequence on human melanoma cells revealed significant off-target effects after 
phosphorothioate application that might contribute to the apoptotic effect of 
Oblimersen. Despite the effective down-regulation of Bcl-2 by both agents, only 
Oblimersen, but not the siRNA sequence, induced apoptosis in human melanoma 
cells, as determined by annexin staining and caspase assay. Phosphorothioate-
treatment caused a reduction in the expression of several proteins linked to 
apoptosis and stress response (among those galectin-1, cofilin-1, GRP78, HSP60, 
nucleophosmin, and peroxiredoxins), whereas the siRNA sequence seemed to be 
highly target specific. Furthermore Oblimersen-treatment caused a down-regulation 
of four glycolytic enzymes (namely enolase-1, PGK-1, PGAM-1 and TPIS), what 
indicates a partial reversion of the cancer-related Warburg effect. The underlying 
mechanism for observed effects may be a blockage of the mitochondrial voltage 
dependent anion channel (VDAC) mediated by the phosphorothioate. Since similar 
effects have been obtained with control phosphorothioates, the observed reversal 
seems not to be caused by the Bcl-2 reduction alone, but rather by the 
phosphorothioate chemistry.  
 4
 Summary 
One focus of modern pharmaceutical research is the investigation of safe and 
efficacious ways of specifically silencing important targets that have been identified to 
play key roles in severe diseases. In this context gene silencing approaches, 
including antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs), 
have great potential as therapeutics. Despite this promising concept and the success 
of so far one approved product, the clinical development of antisense agents is 
challenged with issues regarding site-specific delivery, stability and off-target effects. 
Most antisense agents in late-stage clinical development belong to the group of 
phosphorothioates, such as Oblimersen (Genasense, G3139). The 18mer 
phosphorothioate is directed against Bcl-2, a key protein of the mitochondrial 
apoptotic pathway, and is clinically tested against a variety of different cancers 
including melanoma. The working mechanism of Oblimersen is poorly understood, 
since Bcl-2 silencing is supposed not to be the sole mechanism for 
chemosensitization in melanoma cells [Stein et al., 2009].  
The aim of this work was the establishment of a validated proteomic approach in 
order to monitor and compare potential off-target effects of the phosphorothioate 
Oblimersen and a bcl-2-targeted siRNA on the protein level. Required ASOs and 
siRNAs were synthesized and transfected to the human melanoma cell line 607B, 
which over-expressed the anti-apoptotic target protein Bcl-2. Although both 
sequences successfully down-regulated Bcl-2, only Oblimersen induced apoptosis in 
607B cells after 48 hours of transfection as determined by annexin staining and 
caspase assay. Based on an equal target down-regulation of 75%, differently treated 
cell lysates were investigated by two-dimensional gel electrophoresis and 
subsequent software-based image analysis. Therefore optimization of two-
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 dimensional separation and staining conditions, as well as the validation of 
bioanalytical methods had to be performed in order to obtain reliable quantitative 
proteomic data. Since the used cell line had not been characterized on the protein 
level before, a protein reference map was established. The differential expression of 
22 proteins after Oblimersen-treatment and of 2 proteins after siRNA-treatment, 
monitored by DIGE technology, suggested a higher target specificity for the used 
siRNA compared to the tested phosphorothioate. Changed proteins, which were 
unambiguously identified by in-gel digestion and subsequent MALDI-rTOF-MS, 
included cytoskeletal proteins, chaperons, transport proteins, glycolytic and other 
enzymes, proteins involved in Ca2+-signaling and in redox-regulation as well as other 
proteins, such as galectin-1. Many of these proteins are linked to apoptosis or drug 
resistance. The most interesting result, however, was the observed reduction in the 
expression of glycolytic enzymes after Oblimersen treatment, indicating a partial 
reversal of the Warburg effect [Warburg et al., 1930]. Using the same proteomic 
approach similar effects were obtained with control phosphorothioate-modified 
oligonucleotides targeted at genes not involved in apoptosis.  
Presented findings support the theory that the Bcl-2 reduction is not the only 
essential molecular effect of Oblimersen. An unspecific apoptosis induction, possibly 
caused by a blockage of the voltage-dependent anion channel (VDAC) [Stein et al., 
2008] by the phosphorothioate, seems to play a further key role. Since the discussed 
partial reversal of the Warburg effect has been observed also with control 
sequences, it seems to be caused by the phosphorothioate chemistry and not 
exclusively by bcl-2 targeted gene silencing.  
 6
 Zusammenfassung 
Ein Schwerpunkt der modernen pharmazeutischen Forschung liegt in der 
Erforschung sicherer und effizienter Methoden zur Hemmung bestimmter Gene im 
menschlichen Körper, die mit schwerwiegenden Krankheiten in Verbindung gebracht 
werden. In diesem Zusammenhang haben sogenannte „gene-silencing“ 
Therapeutika, also Substanzen, die spezifische Gensequenzen blockieren können, 
wie zum Beispiel Antisense-Oligonukleotide (ASOs) oder kleine hemmende RNA-
Strukturen (siRNAs), großes Potential als potentielle neue Wirkstoffe. Trotz 
vielversprechender Ansätze und bisher einer Substanz dieser Klasse auf dem Markt, 
ist die erfolgreiche klinische Entwicklung dieser Therapeutika noch mit zahlreichen 
offenen Fragestellungen behaftet, wie etwa hinsichtlich der Stabilität, der Aufnahme 
in die entsprechenden kranken Zellen sowie unspezifischer Effekte mancher 
Substanzen. Die meisten Antisense-Oligonukleotide, die in höheren klinischen 
Studien getestet werden, gehören zur Gruppe der Phosphorthioate, wie zum Beispiel 
Oblimersen (Genasense, G3139), das gegen verschiedene Tumorarten, unter 
anderem gegen Melanome, getestet wird. Dieses 18 Basenpaar lange Oligonukleotid 
hemmt spezifisch ein Protein namens Bcl-2, das eine Schlüsselfunktion in der 
mitochondrialen Apoptose, also im programmierten Zelltod, spielt. Der genaue 
Wirkmechanismus von Oblimersen ist noch nicht völlig geklärt. Es wird aber davon 
ausgegangen, dass die Bcl-2 Hemmung nicht der einzige Mechanismus ist, mit dem 
Oblimersen eine (Re-)Sensibilisierung von Melanomzellen gegenüber 
Chemotherapie erreicht [Stein et al., 2009].  
Das Hauptziel dieser Arbeit bestand darin, potentielle unspezifische Effekte am 
Proteom von Melanomzellen, verursacht durch Oblimersen und durch eine ebenfalls 
gegen Bcl-2 gerichtete siRNA, mit Hilfe einer validierten Proteomuntersuchung dar 
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 zu stellen und zu vergleichen. Benötigte ASOs und siRNAs wurden synthetisiert. 
Anschließend wurde die humane Melanomzelllinie 607B, die das anti-apoptotische 
Zielprotein Bcl-2 über-exprimiert, damit transfiziert. Obwohl beide Sequenzen das 
Zielprotein effektiv herunter regulierten, konnte nach 48 Stunden Transfektion nur bei 
Oblimersen-behandelten Zellen eine Apoptoseinduktion festgestellt werden. 
Basierend auf derselben 75 prozentigen Bcl-2 Hemmung, wurden die unterschiedlich 
behandelten Zelllysate mittels zwei-dimensionaler Gelelektrophorese und 
anschließender Software-gestützter Bildanalyse untersucht. Dazu mußten im Vorfeld 
verschiedene Parameter, unter anderem die Auftrennungs- und Färbebedingungen, 
optimiert und die bioanalytischen Methoden validiert werden. Da die verwendete 
Zelllinie auf Proteinebene noch nicht charakterisiert worden war, wurde eine 
Referenzkarte des Proteommusters erstellt. Mit Hilfe der DIGE Technologie konnte 
eine Beeinflussung der Genexpression von 22 Proteinen nach der Behandlung mit 
Oblimersen und von 2 Proteinen nach der Behandlung mit der siRNA festgestellt 
werden. Dies deutet darauf hin, dass die verwendete siRNA target-spezifischer wirkt 
als das Phosphorthioate. Die in ihrer Expression beeinflußten Proteine wurden im 
Anschluß mittels „in-gel“ Verdau und MALDI-rTOF-MS eindeutig identifiziert. Unter 
ihnen befanden sich Zytoskelett-Proteine, Chaperone, Transportproteine, 
glykolytische und andere Enzyme, Proteine, die in die Ca2+-Regulierung oder in die 
Redox-Regulierung der Zelle involviert waren, und auch andere Proteine, wie zum 
Beispiel Galectin-1. Viele dieser Proteine stehen mit Apoptose oder Therapie-
Resistenzentwicklung in Verbindung. Das interessanteste Ergebnis der Studie war 
jedoch die beobachtete Expressionsreduktion glykolytischer Enzyme nach der 
Behandlung mit Oblimersen, welche auf eine teilweise Umkehr des sogenannten 
Warburg Effekts hinwies [Warburg et al., 1930]. In derselben Proteomuntersuchung 
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wurden ähnliche Ergebnisse mit Phosphorthioat-modifizierten Kontrollsequenzen 
erreicht, die gegen andere, nicht mit Apoptose in Zusammenhang stehende, Gene 
gerichtet waren.  
Die präsentierten Ergebnisse unterstützen die Theorie, dass die bekannte Bcl-2 
Reduktion nicht der einzige essentielle Wirkungsmechanismus von Oblimersen ist. 
Eine unspezifische Apoptoseinduktion, die wahrscheinlich durch eine Blockade des 
VDAC-Proteins („voltage-dependent anion channel“) [Stein et al., 2008] durch das 
Phosphorthioat verursacht wird, dürfte eine weitere entscheidende Rolle spielen. Da 
die erwähnte teilweise Umkehr des Warburg Effektes auch mit den 
Kontrolloligonukleotiden beobachtet wurde, ist es sehr wahrscheinlich, dass diese 
durch die Phosphorthioatmodifikation und nicht nur durch die Bcl-2 Hemmung 
verursacht wird.  
Introduction 
Introduction  
The complexity of the human cell issues a challenge to modern drug discovery, 
which becomes even more important with the elucidation of new signaling cascades 
and protein interactions. The main problems of drug development have shifted from 
the elucidation of cellular targets to the monitoring of off-target and potential adverse 
effects on the whole genome, transcriptome, metabolome and proteome. These 
unspecific effects can be caused directly by the drugs or indirectly by the onset of 
alternative cellular pathways to circumvent treatments. In the best case the 
therapeutic effect of the drug is supported or in rare cases new therapeutic 
perspectives are opened up, in the worst case the therapeutic aim is opposed or 
even unexpected toxicity is caused by unspecific drug interactions [Stessl et al., 
2009]. In any way the elucidation of potential adverse effects of drugs in very early 
phases of drug development is an essential prerequisite for their effective clinical 
use.  
Besides screening of drug candidates over a broad range of different targets, one 
way to contribute to this important question is the investigation of the unspecific drug 
influence on the protein level by a comprehensive proteomic approach, leading to a 
better understanding of intracellular interactions of biological molecules. Especially 
relevant are additional protein changes caused during or after the interaction of a 
drug on a specific cellular target. The specific and rational targeting of key genes, 
identified to play essential roles in various severe diseases, has led to the successful 
development of therapeutic antibodies, small molecules (such as polyamides 
[Dickinson et al., 2004], isoxazolidines, which act as activator artificial transcription 
factors [Rowe et al., 2007], or PARP-1 inhibitors [Tong et al., 2009]) or nucleic acid 
based therapies, such as antisense oligonucleotides (ASOs). In contrast to 
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Introduction 
therapeutic antibodies, which act at the protein level, gene regulation by so-called 
“antisense” oligonucleotides is mainly performed on the genetic level. Despite 
effective target gene down-regulation, antisense agents are confronted with reports 
about (un)desired (un)specific off-target effects, which represent a major safety issue 
with respect to their successful clinical development. Based on this background this 
thesis focused on the investigation of protein changes on human melanoma cells 
caused by the application of two different oligonucleotides, namely the 
phosphorothioate Oblimersen and a bcl-2-targeted small interfering RNA (siRNA).  
 
1. Nucleic acid-based therapy 
Nucleic acid-based therapeutics comprehend a variety of molecules with different 
rationales and mechanisms, including therapeutic nucleotides and nucleosides, oligo- 
and polynucleotides. Although therapeutic nucleotides and nucleosides interfering 
with nucleic acid metabolism and DNA polymerization have been successfully used 
as anticancer and antiviral drugs, they often produce toxic secondary effects related 
to dosage and continuous use [Alvarez-Salas, 2008]. Newer treatment strategies with 
high affinity to their biological targets, among others, include DNA vaccines, which 
are based on the activation of the human immune system by a plasmid DNA 
encoding for a foreign protein resulting in antibody production [Nemunaitis et al., 
2009; Tüting et al., 2000], or ribozymes, catalytically active RNA molecules capable 
of site-specific cleavage of target mRNA [Bhindi et al., 2007]. So far, the most 
promising nucleic acid-based strategies with regard to clinical development are 
aptamers and antisense oligonucleotides (ASOs), with two approved products for 
local administration at the eye (the antisense oligonucleotide fomivirsen (Vitravene; 
Isis Pharmaceuticals) and the aptamer pegaptanib (Macugen, Macuverse; NeXstar 
 11
Introduction 
Pharmaceuticals)). Aptamers are small single-stranded nucleic acids that fold into 
well-defined three-dimensional structures and bind their target with high affinity and 
specificity [Mayer, 2009]. Antisense oligonucleotides are small single-stranded DNA 
strands, the concept of which dates back to the work of Zamecnik and Stephenson 
[Zamecnik et al., 1978] and is discussed below. Furthermore small interfering RNAs 
(siRNAs), which have been discovered about one decade ago [Fire et al., 1998], 
represent a rapidly developing nucleic acid-based strategy, which is discussed in the 
next chapter.  
Actual challenges for a successful clinical development of therapeutic 
oligonucleotides refer to partly understood pharmacokinetics, poor bioavailability, 
ineffective drug delivery and/or insufficient uptake into target cells, as well as the 
problem of specificity [Stein et al., 1993]. The question of the interaction of different 
cellular pathways activated upon application of the drug strongly influences its 
therapeutic effect.  
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Introduction 
1.1 Antisense oligonucleotides (ASOs) 
As well as any other gene-silencing strategy the antisense concept derives from an 
understanding of nucleic acid structure and function depending on Watson-Crick 
hybridization [Watson et al., 1953]. Antisense oligonucleotides (ASOs), which are 
short single-stranded DNA sequences (10-30 nts [Opalinska et al., 2002] or 13-35 nts 
[Mahato et al., 2005], respectively), are designed to specifically modulate translation 
of a particular gene into a protein by hybridizing and disrupting the function of pre-
mRNA and mRNA, thereby preventing the mRNA from being translated [Monia et al., 
2001]. Among several described gene expression inhibition mechanisms by ASOs 
[Noe et al., 2000; Opalinska et al., 2002; Bennett et al., 2010] the most relevant is the 
degradation of the mRNA by RNase H activated at the site of ASO binding [Baker et 
al., 1999]. RNase H is abundant in the cytoplasm and nucleus and functions as an 
endonuclease to recognize and cleave the RNA moiety of the formed RNA-DNA 
hybrid [Mahato et al., 2005; Achenbach et al., 2003]. The ASO is undamaged by the 
enzymatic attack and is free to hybridize with the next RNA molecule, thus 
functioning in a catalytic manner [Opalinska et al., 2002]. The understanding of the 
ASO mechanism has led to the design of different chemical modifications of the 
phosphate backbone, the sugar components or the nucleobases in order to improve 
the most important features of ASOs, like binding affinity, base-pair specificity, 
nuclease resistance, support of endonucleolytic cleavage, chemical stability, 
lipophilicity, solubility and protein-binding as well as pharmacological properties 
[Cook, 2001; Noe et al., 2000; Urban et al., 2003; Winkler et al., 2004]. 
Phosphorothioates, ASOs which contain a sulphur substitution in the backbone 
phosphate linkage, are referred to as first generation compounds and showed 
enhanced stability against tissue nucleases and improved plasma half-lifes [Eckstein, 
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2000]. Most of ASOs in late-stage clinical development, as well as the only launched 
compound, fomivirsen (Vitravene), are phosphorothioates (table 1). 
Second generation antisense compounds are based on 2’-O-alkyl derivatives [Cotten 
et al., 1991], which have exhibited superior in vitro characteristics. Prominent 
representatives are 2’-O-methoxyethyl (2’-MOE) derivatives showing increased 
resistance to plasma and tissue breakdown and improvements in the affinity with 
which they bind RNA [Monia et al., 1993]. Subsequently more rigorous chemical 
modifications have been introduced in order to increase stability and target affinity, 
such as zwitterionic compounds [Noe et al., 2005; Winkler et al., 2004, 2007 and 
2008], morpholino oligonucleotides [Summerton, 1999 and 2007] and locked nucleic 
acids (LNA) [Jepsen et al., 2004; Simoes-Wüst et al., 2004] as the most promising 
therapeutic derivatives (table 1). 
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Compound Chemistry Target Clinical Technologies Indications 
Status
fomivirsen [Vitravene] phosphorothioate IE2 of CMV virus launched intravitreal CMV retinitis
pegaptanib [Macugen, aptamer VEGF165 launched iv., ophthalmic formul. age related macular degeneration, 
Macuverse] retinal venous occlusion
aprinocarsen [Affinitak] phosphorothioate PKC alpha discontinued iv. solid tumor, NSCLC
(03/05)
oblimersen (G-3139) phosphorothioate bcl-2 phase III iv., infusion melanoma; chronic lymphocytic leukemia;
[Genasense] multiple myeloma; non-small cell lung cancer; 
Non-Hodgkin lymphoma, B-cell lymphoma; 
breast, colorectal and prostate tumor
trabedersen (AP-12009) phosphorothioate TGF beta 2 phase III intratumoral, iv glioma, melanoma, solid tumors
aganirsen (GS-101) phosphorothioate IRS-1 phase III ophthalmic formul. retinopathy, glaucoma
mipomersen (ISIS-301012) 2'-methoxyethyl apoB-100 phase III sc. hypercholesterolemia, cardiovascular disease
mod. phosphorothioate
belagenpumatucel-L [Lucanix] antisense-based cancer vaccine TGF beta phase III intradermal lung cancer, glioma
alicaforsen (ISIS-2302) phosphorothioate ICAM-1 phase III iv., rectal inflammatory disease, ulcerative colitis, asthma
bevasiranib (Cand5) siRNA VEGF phase III ophthalmic formul. age related macular degeneration; 
diabetic macular edema
(AEG-35156) phosphorothioate XIAP phase II iv. cancer (among leukemia, NSCLC, lymphoma)
(AGN-211745, AGN-745) siRNA VEGFR-1 phase II intravitreal age related macular degeneration
(ALN-RSV01) siRNA respiratory syncytial phase II inhalant, nasal formul. respiratory syncytial virus infection
virus N gene
(ASM-8, TPI-ASM-8) combination of two ASOs IL-3 beta, IL-5, GM-CSF phase II inhalant formulation asthma
(AVI-4126) [Resten-NG/MP]  c-myc phase II iv, microparticle formul. restenosis, renal disease, cancers
cenersen (EL-625) [Aezea] phosphorothioate p53 phase II iv. leukemias (AML, CLL), lymphoma 
custirsen (OGX-011) 2'-methoxyethyl clusterin phase II iv. solid tumor
mod. phosphorothioate
(DIMS-0150) [Kappaproct] NF-kappaB p65 phase II rectal inflammatory disease, ulcerative colitis, 
cerebral edema
 
Table 1. Overview of therapeutical oligonucleotides in clinical phases II or III according to the IDdb3 (The Investigational Drugs database, 
www.iddb3.com), date august 2009. Round brackets: research code; square brackets: trade name. Abbreviations: VEGF: vascular endothelial 
growth factor; PKC: protein kinase C; TGF: transforming growth factor; IRS-1: isulin receptor substrate 1; apoB-100: apolipoprotein B-100; 
ICAM: intercellular adhesion molecule; XIAP: X-linked inhibitor of apoptosis protein; GM-CSF: granulocyte-macrophage colony-stimulating 
factor. 
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Compound Chemistry Target Clinical Technologies Indications 
Status
(EHT-899) DNA therapeutic HBV virus phase II oral Hepatitis B virus infection
(EZN-2968) Locked Nucleic Acid HIF-1 alpha phase II iv. formulation cancer
(HGTV-43) retrovirus-based stem cell therapy HIV virus phase II iv. HIV infection
(ISIS-113715) 2'-0-methoxyethyl modified ASO PTP-1B phase II iv. type 2 diabetes
(LOR-2040, GTI-2040) phosphorothioate R2 ribonucleotide reductase phase II iv. cancer (among AML, renal tumor)
(LOR-2501) phosphorothioate R1ribonucleotide reductase phase II iv. lymphoma, prostate cancer 
(LY-2181308, ISIS-23722) survivin phase II iv. AML, prostate cancer
(PF-04523655, REDD-14-NP) modified siRNA hypoxia-inducible gene phase II iv., ophthalmic age related macular degeneration; 
RTP801 formulation diabetic macular edema
(QPI-1002) siRNA p53 phase II iv. kidney transplant rejection, renal injury
ranagengliotucel-T [Glionix] antisense-based cancer vaccine TGF beta 2 phase II brain cancer
(RPI-4610) [Angiozyme] ribozyme VEGFR-1 phase II sc. colorectal tumor
(RX-0201) [Archexin] AKT protein kinase phase II iv. solid tumor (among renal cell carcinoma, 
pancreatic cancer)
(SPC-2996) Locked Nucleic Acid bcl-2 phase II iv. cancer (CLL)
(TV-1102, ISIS-107248) integrin alpha-4/beta-1 phase II sc. inflammatory disease, multiple sclerosis
(CD49d)
 
Table 1 continuation. Abbreviations: HIF-1: hypoxia-inducible factor 1; PTP-1B: Protein tyrosine phosphatase 1B; TGF: transforming growth 
factor; VEGFR: vascular endothelial growth factor receptor. 
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In 2006 the voltage-dependent anion channel (VDAC) was first identified as a 
potential pharmacologic target of phosphorothioates in melanoma cells [Lai et al., 
2006; Tan et al., 2007]. VDAC has been widely implicated in the initiation of the 
mitochondrially mediated intrinsic pathway of apoptosis maybe by a decrease in 
metabolic flux and subsequent permeabilization of the mitochondrial outer membrane 
to small proteins and cytochrome c, followed by an activation of caspase-dependent 
apoptosis [Stessl et al., 2009]. Furthermore VDAC has been characterized as 
important component involved in mitochondrial membrane cholesterol distribution, 
which in turn might be related to a type of aerobic glycolysis for energy production 
present in most tumor types, widely known as Warburg effect [Campbell et al., 2008]. 
Phosphorothioate oligonucleotides were found to be potent and specific inhibitors of 
this channel protein [Stein et al., 2008]. 
 
Despite the steadily improving medicinal chemistry, the therapeutical efficiency of 
ASOs is often impeded by poor bioavailability, inefficient drug delivery and most 
important by off-target effects [Anderson et al., 2006; Gjertsen et al., 2007], leading 
to an obscurity of the antisense mode of action and, in some cases, causing cellular 
toxicity [Eckstein et al., 2000]. The best characterized classes of antisense drugs with 
respect to such toxicities are first-generation phosphorothioates and second-
generation 2’-MOE modified antisense oligonucleotides [Bennett et al., 2010]. Off-
target effects of phosphorothioates can be generally caused by the actual reduction 
in target protein expression itself in a hybridization-dependent process, by antisense 
hybridization with related or nearly homologous sequences on nontarget mRNA and, 
most important, by nonspecific interactions with proteins [Levin et al., 2001]. 
Toxicities caused by exaggerated pharmacological effects (that means by excessive 
Introduction 
target down-regulation) and hybridization to nontarget RNAs can be avoided or 
minimized by proper selection of the target RNA and careful characterization of the 
pharmacology and toxicology of antisense inhibitors in preclinical models. Off-target 
hybridization-dependent effects can be minimized by performing careful 
bioinformatics analyses to identify targets with perfect mismatches or one to three 
mismatches [Bennett et al., 2010]. The most prominent class-related toxicological 
effects observed in clinical studies after systemic administration are all related to 
nonspecific interactions with proteins and include complement activation, 
prolongation of clotting times (inhibition of the coagulation cascade), immune 
stimulation, pro-inflammatory action and reactions at the injection site [Levin et al., 
2001]. These effects are dose dependent and tend to occur at high doses of the 
oligonucleotides. They can be either sequence-dependent, such as interaction with 
Toll-like receptors, or sequence independent [Bennett et al., 2010]. Toll-like receptor 
9 has been identified to recognize specific CpG dinucleotide motifs of antisense 
oligonucleotides, leading to the rapid activation of cell signaling pathways, including 
mitogen-activated protein kinases and NF-κB [Krieg et al., 2003]. CpG-containing 
ASOs have been shown to trigger humoral immunity by inducing B-cell activation, 
proliferation and interleukin-6 and IgM secretion [Krieg et al., 2003]. 
Besides the problem of specificity, a sufficient uptake of intact ASOs into the cell 
represents a significant challenge to the therapeutical use of these large molecules 
which usually harbour many solvent-exposed negative charges. The uptake appears 
to be an active, highly variable process dependent on cell type, time, concentration, 
energy, temperature, saturation, sequence and type of the oligonucleotide. From the 
application site ASOs need to be released from endosomes after endocytosis, travel 
to the cell surface, cross the plasma membrane and migrate to the cyto- or 
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nucleoplasm in order to reach the target mRNA. Phosphorothioates have been 
described to be taken up by receptor-mediated endocytosis at lower concentrations, 
but via fluid-phase endocytosis at higher concentrations [Mahato et al., 2005]. 
Typically oligonucleotides are administered by intravenous injection and infusion. 
Routes of administration, however, have been expanded over the last decades 
including also topical application to the skin, enema, inhalation and subcutaneous 
injection. Research efforts are rapidly advancing even oral formulations (across the 
gut wall) of oligonucleotides toward the clinic [Akhtar, 2009]. Oligonucleotides have 
been modified by appending lipophilic substituents, ligands for cell surface receptors, 
or cell-penetrating peptides to enhance their delivery to the cytoplasm, [Bennett et 
al., 2010].  
The therapeutical spectrum of antisense agents actually tested in the clinic is wide 
(table 1), including cardiovascular disease, inflammation, infection and, above all, 
cancer [Crooke, 2004]. Diseases that are characterized by over-expression or 
inappropriate expression of specific genes, or genes that are expressed by invading 
microorganisms, are candidates for this therapeutic approach. Malignant diseases, in 
particular, are attractive candidates, since conventional cancer therapies are highly 
toxic and affect also normal cells [Opalinska et al., 2002]. Nevertheless many clinical 
studies in the field of oncology failed to reach their end points and so far the 
antisense concept could not fulfill all expectations. The best example is the 18mer 
phosphorothioate Oblimersen (G-3139, Genasense, Genta Inc., Berkeley Heights, 
NL, USA), which is directed against the first six codons of the anti-apoptotic bcl-2. 
Oblimersen selectively reduces bcl-2 mRNA and subsequently decreases the 
expression of the protein Bcl-2, which plays a key role in preventing programmed cell 
death (id est apoptosis) [Willis et al., 2003]. The effective knock-down of this protein 
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is critical to tumor cell survival and positively influences the resistance of human 
malignancies towards standard chemotherapy [Wacheck et al., 2002].  
 
Figure 1. Phosphorothioate structure. 
 
Multiple phase I, II and III clinical trials of Oblimersen alone or in combination with 
other anticancer agents have been conducted or are still going on in various cancer 
types (table 1) including advanced melanoma [Tarhini et al., 2007]. As chemotherapy 
resistance in melanoma has been related to anti-apoptotic effects mediated by Bcl-2 
[Jansen et al., 2000], it was tested whether Bcl-2 inhibition by Oblimersen would 
improve the efficacy of standard chemotherapy [Bedikian et al., 2006]. After the 
largest study ever conducted for advanced melanoma using a combination of 
Oblimersen and dacarbazine compared to dacarbazine monotreatment, overall 
survival, set as the primary end point, failed to reach the statistical significance level 
of p<0.05 [Bedikian et al., 2006]. Although results of this trial showed increased 
secondary end points, including progression free survival and response rates, the 
results were not enough for FDA approval ultimately. Closer examination of the 
results confirmed serum lactate dehydrogenase (LDH) as a potent prognostic 
biomarker for malignant melanoma, since patients with normal LDH levels were more 
likely to benefit from the Oblimersen-dacarbazine regimen including statistically 
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significant prolongation of overall survival [Agarwala et al., 2009]. Consequently, 
Genta Inc. has decided to conduct a new phase III trial recruiting only patients with a 
maximum of 80% of normal LDH serum levels [Agarwala et al., 2009]. Observed 
adverse events of the Oblimersen treatment have included fatigue, 
myelosuppression, transient thrombocytopenia, leukopenia, anemia and 
lymphopenia. Dose-related, reversible changes in liver function tests (aspartate 
aminotransferase, alanine aminotransferase, bilirubin and/or alkaline phosphatase) 
have been observed after prolonged infusion (14 days or longer), but these and other 
side effects are uncommon with shorter infusions [Tarhini et al., 2007].  
The exact molecular mechanism of action of Oblimersen and its impact on non-target 
proteins has not been clarified up to now. The success of antisense therapy and the 
effective use of phosphorothioates in the clinic will be strongly dependent on the 
identification of involved cellular signaling pathways and intracellular interactions with 
proteins playing key roles in malignant processes such as proliferation, angiogenesis 
and apoptosis. 
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1.2 RNA interference (RNAi) 
RNA interference is a naturally occurring biological process in which small 21-23 
[Mahato et al., 2005] or 21-28 [Rao et al., 2005] nucleotide duplexes (small 
interfering RNAs, siRNAs), respectively, silence a target gene by binding to its 
complementary mRNA thereby triggering its elimination [Mahato et al., 2005]. The 
silencing process by siRNA occurs post-transcriptionally in the cytoplasm [Zeng et 
al., 2002] and it is an ATP-dependent event. It was first discovered in Caenorhabditis 
elegans [Fire et al., 1998] and has most likely evolved as a mechanism for cells to 
eliminate unwanted foreign genes. The physiological functions of RNAi are described 
to be a defense against viral infections, cell fate specification, transposon silencing 
and the regulation of developmental pathways [Rao et al., 2005; Milhavet et al., 
2003].  
The discovery of RNAi has revolutionized the field of gene silencing strategies and 
has prompted intensive research efforts in the last decade [Mello et al., 2004; Grimm, 
2009], thereby benefitting very much from earlier acquired knowledge about ASO 
structures and functions. In essence, long stretches of double stranded RNA 
(dsRNA) undergo processing by an enzyme referred to as Dicer, which cuts long 
stretches into duplexes with 19 paired nucleotides and two nucleotide overhangs at 
both 3’-ends [Elbashir et al., 2001]. These double-stranded siRNAs then associate 
with the RNA-induced silencing complex (RISC), a large (approximately 160 kDa) 
protein complex comprising Argonaute proteins as the catalytic core [Tang, 2005]. 
Argonaute proteins are higly basic proteins which contain two common domains, 
PAZ and PIWI. The PIWI domain is essential for interaction with Dicer and contains 
the nuclease activity that cleaves off target mRNAs [Sioud, 2007]. Within RISC the 
siRNA is unwound and the sense strand is removed for degradation by cellular 
 22
Introduction 
nucleases. The antisense strand of the siRNA directs RISC to the target mRNA 
sequence, where it anneals complementarily by Watson-Crick base pairing. Finally 
the target mRNA is degraded by RISC endonuclease activity [Cejka et al., 2006]. In 
2001, Tuschl and co-workers provided the first evidence that siRNAs can mediate 
sequence-specific gene silencing in mammalian cells bypassing the Dicer step by 
direct transfection of siRNA molecules into cells [Elbashir et al., 2001], which opened 
up the way towards a use as tool and potential therapeutic.  
The leading application for RNAi technology to date is the in vitro study of gene 
knockdown, because RNAi represents a fast and reliable tool for the characterization 
and influence of gene knockdown phenotypes [Cejka et al., 2006]. As they have 
benefitted very much from the antisense experiences made before, the first siRNA 
candidates have rapidly entered the clinic (table 1), with bevasiranib (Cand5), an 
anti-VEGF-siRNA, being actually tested in phase III against age related macular 
degeneration. Main therapeutic applications include viral infections, neurological 
disease, oncology, ocular disease as well as inflammation and apoptosis [Uprichard, 
2005]. The high sequence specificity of RNA interference may provide a means of 
inhibiting even the expression of single alleles, while the essential wild type allele is 
not inhibited. This is of great interest for neurodegenerative disorders that results 
from dominant mutations in a single allele, such as Parkinson`s disease, 
Huntington’s disease or amyothrophic lateral sclerosis [Uprichard, 2005]. RNAi might 
also complement chemotherapy in the treatment of patients that have developed 
multidrug resistance. 30% of all cancers develop resistance to standard 
chemotherapy due to an elevated expression of the multidrug resistance gene (MDR-
1) [Tsuruo et al., 2003]. RNAi-mediated suppression of MDR-1 has been shown to 
re-sensitize cells to chemotherapy [Nieth et al., 2003]. 
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The developmental progress has required 10-15 years for ASOs but only 2-4 years 
for RNAi, since both strategies – apart from fundamental differences in the mode of 
action - have many similarities (table 2) [Corey, 2007]. RNAi effectors can be 
delivered to cells using either synthetic siRNAs or DNA, which encode for short 
hairpin RNA (shRNA) expression cassettes which are processed into active siRNAs 
by the host cells [Uprichard, 2005]. Actual clinical trials use intravenous and 
ophthalmic formulations of siRNAs, since RNAi technology is facing similar in vivo 
challenges compared to ASOs, such as limited stability, the problem of delivery as 
well as safety issues including off-target and nonspecific effects. siRNAs have been 
assumed to be higly specific and small enough to evade the immune system, but up 
to now several off-target effects, among them immunostimulatory effects, have been 
observed even in low nanomolar concentrations [Sioud et al., 2003]. siRNAs have 
activated the interferon-regulated double-stranded RNA-dependent protein kinase 
(PKR) and endosomal Toll-like receptors (TLRs), a family of transmembrane 
proteins, which play a crucial role in microbe recognition and activation of innate and 
adaptive immunity [Sioud et al., 2007]. Certain sequences have stimulated 
monocytes via TLR-8 or dendritic cells via TLR-7 to produce proinflammatory 
cytokines and large amounts of interferon α, respectively. Immunostimulatory siRNA 
effects are sequence dependent and can occur with double- and single-stranded 
siRNAs. Although GU dinucleotides have been found to trigger TLR-7 and TLR-8 
activation, the absolute requirement in siRNA activation of innate immunity is still not 
clear [Sioud et al., 2007]. Furthermore, interactions with undesired target mRNAs 
leading to the destruction of genes unrelated to target silencing have been observed 
[Jackson et al., 2003; Scacheri et al., 2004]. 2′-uridine modifications of siRNAs, 
however, have been reported to evade immune activation and to reduce mentioned 
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off-target effects [Cekaite et al., 2007]. With regard to an improvement of stability and 
cellular uptake of therapeutically relevant siRNAs, many of the precedent antisense 
modification concepts are used, including direct chemical alterations of nucleic acids 
and various methods of packaging the effector into protective particles [Uprichard, 
2005]. 
Similarities and differences between antisense oligonucleotides (ASOs) and siRNA
Similarities
Short (~20 bases) nucleic acids
Common methods for delivery to cultured cells
Induce post-transcriptional gene silencing by targeting mRNA
siRNA and many ASOs cause mRNA cleavage
Properties can be altered by introducing modified bases
Similar biodistribution profiles
Differences
Two strands for siRNA, one strand for ASOs
Unmodified duplex RNA is more stable than unmodified single-stranded RNA or DNA 
In cultured cells, chemical modifications are much less necessary for siRNA than for ASOs
Effects of siRNA mediated by the RISC complex
ASOs act by activation of RNAse H or steric inhibition
Rapid and widespread adoption of siRNA among biomedical researchers
 
 
Table 2. Adapted from Paroo and Corey, 2004. 
 
The theoretical discussion, which of the two described antisense strategies is 
superior can only be solved by clinical development. Antisense oligonucleotides have 
the advantages that they are half the molecular weight and do not require a 
hybridization step, thus simplifying large-scale preparation of drugs. Furthermore the 
introduction of a synthetic RNA may perturb the native machinery resulting in in vivo 
toxicities, since endogenous duplex RNAs control important physiologic processes 
[Corey, 2007]. These potential advances are balanced against high potencies of 
siRNAs. In various in vitro models siRNAs have shown to be effective in already very 
low nanomolar concentrations (5-100nM compared to 50-400nM of ASOs) [Cejka et 
al., 2006]. Most likely ASOs may have chemical and biological properties that might 
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be superior for some tissues and gene targets, whereas siRNAs may be superior for 
others [Corey, 2007].  
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2. B-cell lymphoma 2 (Bcl-2) 
2.1 Bcl-2 and apoptosis 
Apoptosis is a programmed cell death mechanism involving two distinct but 
converging pathways and is generally characterized by sequential activation of 
cysteine proteases of the caspase family (figure 2) [Adams, 2003; Sun et al., 2001]. 
The core of the intrinsic apoptotic machineries, which are mainly regulated by 
proteins of the B-cell lymphoma 2 (Bcl-2) family, is built by mitochondria. Additionally, 
the extrinsic pathway is driven by cell surface receptors of the tumor necrosis factor 
receptor gene superfamily (including TNFR-1, Fas/CD95 and TRAIL [Ashkenazi, 
2002]), which activate Caspase-8 (and Caspase-10 in humans) when their ligand-
mediated trimerization on the plasma membrane recruits the adaptor protein FADD 
(Fas-associated death domain protein) and the caspase into multi-protein complexes 
[Adams et al., 2007]. In many cell types, however, death receptor-mediated apoptotic 
signaling induces a mitochondrial death amplification loop via proteolytic activation of 
the BH3-only protein Bid [Gul et al., 2008]. The intrinsic pathway (also termed as 
‘mitochondrial’ or ‘stress’ pathway), which has been extensively reviewed (Adams et 
al., 2003 and 2007; Danial et al., 2004), activates Caspase-9 on the scaffold protein 
Apaf-1 when cytochrome c is released from damaged mitochondria in response to 
diverse stresses, including cytokine deprivation and DNA damage. These initiator 
caspases can cleave and activate the effector caspases (Caspase-3, Caspase-6, 
and Caspase-7) that mediate cellular demolition by cleaving multiple critical cellular 
proteins [Adams et al., 2007].  
Defects in apoptotic signaling can be a cause or contributing factor in a variety of 
diseases, including cancer (resistance to chemotherapy, defective tumor surveillance 
by the immune system), autoimmunity (accumulation of autoreactive lymphocytes) 
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and infection (accumulation of infected cells), as well as neurodegeneration 
(excessive apoptosis in e.g. Alzheimer’s disease, Parkinson’s disease or 
amyotrophic lateral sclerosis), AIDS (excessive depletion of T cells) or ischaemia 
(stroke, myocardial infarction) [Reed, 2002; Fischer et al., 2005].  
 
 
 
Figure 2. Illustration of the two major apoptotic pathways (picture taken from MacFarlane et 
al., 2004). 
 
 
The bcl-2 gene and protein product were originally described following the 
identification of the t(14;18) chromosome translocation in follicular B-cell non-
Hodgkin lymphoma cells [Tsujimoto et al., 1984 and 1987]. The protein Bcl-2 itself is 
referred to as the prototypic anti-apoptotic protein belonging to a superfamily of 
proteins (n=24 in humans [Reed, 2003]), which includes pro-survival representatives 
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(among others Bcl-2, Bcl-xL, Bcl-w, A1 and Mcl-1) as well as pro-apoptotic members 
(the Bax-subfamily including Bax, Bak and Bok, and the BH3-only proteins, including 
Bad, Bik, Bid, Bim, Bmf, BNIP3, Noxa and Puma) [Cory et al., 2002]. Most Bcl-2 
family members, apoptosis agonists and antagonists, have Bcl-2 homologous (BH) 
regions, designated as BH1-BH4 (figure 3), which determine their capacity to interact 
with other Bcl-2 proteins and with the mitochondrial membrane [Tolcher, 2005].  
 
 
 
Figure 3. Scheme of Bcl-2 family members. BH – Bcl-2 homology domain; TM – 
transmembrane domain; picture taken from Bush et al., 2003. 
 
 
One of the key events in cell death is an increase of the mitochondrial membrane 
permeability leading to a loss of ΔΨ (mitochondrial inner transmembrane potential), 
mitochondrial swelling, and rupture of the outer mitochondrial membrane [Tsujimoto 
et al., 2007]. As a result pro-apoptotic molecules are released to the cytosol 
(including cytochrome c, apoptosis-inducing factor AIF, endonuclease G, 
Smac/Diablo and Htr/Omi [Gul et al., 2008]) which trigger the further activation of the 
 29
Introduction 
caspase cascade. Whether apoptosis or cell survival is favored is controlled by Bcl-2 
proteins through the competitive dimerization between selective pairs of death 
antagonists and agonists of this family [Coultas et al., 2003]. Upon cell death stimuli, 
the pro-apoptotic proteins Bax and Bak are activated, inserted into the outer 
mitochondrial membrane and oligomerized, thereby facilitating mitochondrial outer 
membrane permeability (MOMP) either by forming channels by themselves 
[Antonsson et al., 2000] or by interacting with components of the so-called 
permeability transition pore (PTP). This pore putatively consists of the voltage-
dependent anion channel (VDAC), the adenine nucleotide translocator (ANT), 
cyclophilin D (Cyp D: a mitochondrial peptidyl prolyl-cis, trans-isomerase) and other 
molecules [Tsujimoto et al., 2007].  
Anti-apoptotic Bcl-2 proteins act as gatekeepers of MOMP through binding and 
sequestering pro-apoptotic Bax and Bak (figure 4). Activated BH3-only proteins, 
which differ in their potency among each other (Bim, Puma and truncated Bid (tBid) 
can bind all pro-survival proteins, whereas the selective proteins Noxa and Bad can 
only sequester Bcl-2 and Bcl-xL) play another important role in the apoptosis 
cascade. They trigger apoptosis either by directly sequestering Bax and Bak as 
activators and by inhibiting pro-survival proteins Bcl-2 and Bcl-xL (figure 4a, direct 
activation model) or by binding only to their pro-survival relatives (figure 4b, indirect 
activation model). In the first model, the remaining BH3-only proteins, termed 
sensitizers, function by binding to the pro-survival proteins, thereby freeing any 
bound Bim or tBid to directly activate Bax and Bak. In the second, according to the 
author more probable indirect activation model, BH3-only proteins trigger apoptosis 
solely by binding to their pro-survival relatives, thereby preventing those guardians of 
cell survival from inhibiting Bax and Bak [Gul et al., 2008; Adams et al., 2007].  
 30
Introduction 
 
 
 
  
Figure 4. Actually discussed models of the roles of Bcl-2 family proteins in the apoptosis 
cascade. Picture taken from Adams et al., 2007. 
 
 
Mitochondrial membrane permeability transition is Ca(2+)-dependent [Tsujimoto, 2007] 
and is linked to increased generation of reactive oxygen species (ROS) [Kroemer et 
al., 2000].  
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2.2 Bcl-2 and cancer 
In many cancer types such as melanoma [Jansen et al., 2000], ovarian carcinoma 
[Williams et al., 2005] or leukemia [Bachmann et al., 2007] over-expression of anti-
apoptotic Bcl-2 proteins has been associated with cell survival and increased 
resistance to chemotherapy (including most cytotoxic anticancer drugs [Reed, 2003]). 
Supposedly high levels of Bcl-2 inhibit apoptosis, among others by suppressing the 
generation of ROS, stabilizing ΔΨ or preventing membrane permeability transition 
and consequently blocking the release of cytochrome c [Reed, 1998]. In melanoma, 
for instance, the expression of Bcl-2 protein has been shown in some studies with 
high frequency (90-100% of tumor biopsies). Moreover, Bcl-2 has been found in 
normal melanocytes, and the loss of Bcl-2 function in Bcl-2 knockout mice leads to 
accelerated disappearance of melanocytes. Depleting Bcl-2 simultaneously with the 
administration of chemotherapy may amplify apoptotic activity and improve clinical 
outcome of therapy, what has been demonstrated in preclinical studies with Bcl-2 
antisense therapy having shown down-regulation of Bcl-2 protein and apoptosis 
induction in numerous solid and hematologic malignancies, including metastatic 
melanoma [Tarhini et al., 2007].  
Various therapeutical concepts have been established targeting key components of 
the apoptotic machinery. Up to now, most of the key players in cellular apoptosis 
regulation are identified and can be targeted by developed therapies. These include 
death receptors triggering apoptosis from the cell surface, Bcl-2 proteins as the 
gatekeepers of the mitochondrial pathway, caspases as the executioner enzymes or 
endogenous caspase inhibitors [Fischer et al., 2005]. Attempts to overcome the 
cytoprotective effects of Bcl-2 and Bcl-xL in cancer include three strategies: (1) 
shutting off gene transcription, (2) inducing mRNA degradation with antisense 
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oligonucleotides (Genasense; ISIS 22783) and (3) directly attacking the proteins with 
small-molecule drugs (Bcl-2 blockers; Tetrocarcin A; Antimycin A derivatives) [Reed, 
2003; Fischer et al., 2005].  
It is assumed that cancer cells depend more on apoptosis suppression than normal 
healthy cells, due to aberrations in proto-oncogene activity and/or cell cycle 
checkpoint control. Exploiting this differential dependence on apoptosis-suppressing 
mechanisms will contribute to an improved understanding of cell death pathways and 
will hopefully lead to improved clinical outcomes. It is of great importance, however, 
to determine to what extend toxicity and off-target effects to normal tissues limits 
application of apoptosis-based therapies for cancer treatment [Reed, 2003].  
Aim of the work 
Aim of the work  
The sucessful clinical development of therapeutically relevant oligonucleotides, such 
as phosphorothioates or small interfering RNAs, is challenged with unspecific drug 
effects. These off-target effects can be caused directly or indirectly by the onset of 
alternative cellular pathways, supporting or opposing the therapeutic aim or even 
causing unexpected toxicity.  
The background of this work is based on the controversial question of specificity of 
oligonucleotides, which are therapeutically used or tested in late-stage clinical 
development, and leads to the main aims of this thesis. Is it possible to monitor any 
off-target effects of therapeutically relevant oligonucleotides, id est effects in addition 
to the known influence on the target sequence, on the cytosolic proteome? If yes, will 
these potential off-target effects differ among the application of distinct types of 
oligonucleotides, namely phosphorothioates and small interfering RNAs, which show 
the same pharmacodynamic effect on the target protein? In case of a successful 
identification of additionally changed proteins: Would these proteins be of importance 
to the metabolic networks of respective oligonucleotides?  
Potential off-target effects of the phosphorothioate Oblimersen (Genasense, G3139) 
and a bcl-2-targeted siRNA on the proteome of the human melanoma cell line 607B 
have to be compared by the establishment of a validated proteomic approach. To 
ensure reliable results, special emphasis has to be put on the optimization of the 
used methods including two-dimensional separation conditions, gel staining protocols 
and software-based image analysis. Since the used cell line has not been 
characterized on the protein level before, a protein reference map of 607B melanoma 
cells has to be set up. Differentially expressed proteins have to be unambiguously 
identified by tryptic in-gel digestion and subsequent matrix-assisted laser 
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desorption/ionization reflectron time-of-flight mass spectrometry (MALDI-rTOF-MS). If 
any effect on the proteome will be found, the roles of these particular proteins have to 
be investigated whether their abundancy changes are due to secondary effects in 
response to Bcl-2 depletion or indication of off-target effects. The first should be 
observed regardless of the oligonucleotide structure (antisense or siRNA), while the 
latter would likely result only after treatment with either compound.  
The results of this thesis contribute to the elucidation of the molecular impact of 
therapeutically relevant oligonucleotides on the protein level.  
Materials and Methods 
Materials and Methods  
Materials  
DNA and RNA synthesis and purification  
Standard β-cyanoethylphosphoramidites for RNA and DNA synthesis [SAFC, Proligo 
Biochemie, Hamburg, Germany]: 
Standard liquid reagents for DNA and RNA synthesis [SAFC, Proligo Biochemie, Hamburg, 
Germany]: 
Tetraethylthiuram disulfide, recrystallized from ethanol, 0.5M in acetonitrile [Sigma-Aldrich, 
St. Louis, MO, USA]  
Diethyl-pyrocarbonate (DEPC) [Sigma-Aldrich, St. Louis, MO, USA] 
Equipment  
CD quartz cuvette (100-QS) [Hellma, Müllheim, Germany] 
10 column DNA-synthesizer [Polygen™, Langen, Germany] 
Jasco J-810 CD spectropolarimeter [Jasco, Gross-Umstadt, Germany] 
Rotilabo® filter for syringes, 0.45µm [Carl Roth, Karlsruhe, Germany] 
SepPak® Plus C18 cartridges [Waters, Framingham, MA, USA] 
Spectrophotometer, PharmaSpec UV-1700 [Shimadzu Europe, Duisburg, Germany] 
Suprasil® UV-cuvette, QS 284 [Hellma, Müllheim, Germany]  
 
Cell culture  
Amphotericin B [Sigma-Aldrich, St. Louis, MO, USA] 
Annexin-V-FLUOS Staining Kit [Roche Diagnostics, Mannheim, Germany] 
Dulbecco’s Modified Eagle Medium [Gibco™, Invitrogen, Carlsbad, CA, USA] 
Dulbecco’s Phosphate Buffered Saline [Gibco™, Invitrogen, Carlsbad, CA, USA] 
Fetal bovine serum, heat inactivated [Gibco™, Invitrogen, Carlsbad, CA, USA] 
Hank’s Balanced Salt Solution [Sigma-Aldrich, St. Louis, MO, USA] 
HEPES [Gibco™, Invitrogen, Carlsbad, CA, USA] 
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Homogenous Caspase Assay, fluorimetric [Roche Diagnostics, Mannheim, Germany] 
Lipofectamine™ 2000 [Invitrogen, Carlsbad, CA, USA] 
L-Glutamine [Gibco™, Invitrogen, Carlsbad, CA, USA] 
OptiMem® [Gibco™, Invitrogen, Carlsbad, CA, USA] 
Penicillin/Streptomycin [Gibco™, Invitrogen, Carlsbad, CA, USA] 
Protease Inhibitor Cocktail, P8340 [Sigma-Aldrich, St. Louis, MO, USA] 
Sodium Bicarbonate [Gibco™, Invitrogen, Carlsbad, CA, USA] 
Trypsin/EDTA [Gibco™, Invitrogen, Carlsbad, CA, USA] 
Equipment  
6-well plates [Falcon™, BD Biosciences, San Jose, CA, USA]  
24-well plates [Iwaki, Tokyo, Japan] 
96-well plates [Greiner Bio-One, Kremsmünster, Austria] 
Cell culture flasks [Greiner Bio-One, Kremsmünster, Austria] 
Coverslips [Menzel-Gläser, Braunschweig, Germany] 
Fluorescence microscope, Nikon Eclipse 50i [Nikon Instruments Inc., Europe] 
Microplate reader, PolarStar Galaxy [BMG LABTECH, Offenburg, Germany] 
Thoma® cell counting chamber [Hawksley, Lancing, UK] 
 
Gel electrophoresis and Western Blotting  
Coomassie® Brilliant Blue G-250 [Serva Electrophoresis, Heidelberg, Germany] 
Dithiothreitol [Serva Electrophoresis, Heidelberg, Germany] 
ECL Plus Western blotting detection reagent [GE Healthcare, Freiburg, Germany]  
Immobiline™ DryStrip Gels, 18cm [GE Healthcare, Freiburg, Germany] 
Iodoacetamide [Serva Electrophoresis, Heidelberg, Germany] 
IPG buffers [GE Healthcare, Freiburg, Germany] 
Precision Plus ProteinTM Standard, All Blue and Unstained [Bio-Rad Laboratories, München, 
Germany] 
PVDF blotting membrane, Immun-Blot® [Bio-Rad Laboratories, München, Germany] 
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Silver nitrate, p.a. [ACROS Organics, Geel, Belgium] 
SYPRO® Ruby Protein Gel Stain [Bio-Rad Laboratories, München, Germany] 
Primary antibodies 
Actin, (A 2066) [Sigma-Aldrich, St. Louis, MO, USA] 
Bcl-2, monoclonal (13-8800) [Zymed® Laboratories, Invitrogen, Carlsbad, CA, USA] 
Secondary antibodies 
Goat anti-mouse IgG HRP, (sc-2005) [Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA] 
Goat anti-rabbit IgG HRP, (sc-2004) [Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA] 
Equipment  
1D-gel electrophoresis devices, Mini-Protean® 3 [Bio-Rad Laboratories, München, Germany] 
2D-gel electrophoresis devices, Protean® II xi [Bio-Rad Laboratories, München, Germany] 
DeCyder™ 2D differential analysis software, version 6.5 [GE Healthcare, Freiburg, Germany] 
Ettan™ IPGphor™ isoelectric focussing unit [GE Healthcare, Freiburg, Germany] 
Imaging Densitometer GS-710 [Bio-Rad Laboratories, München, Germany] 
Molecular Imager ChemiDoc™ XRS System [Bio-Rad Laboratories, München, Germany] 
PD-Quest™ Advanced 2D analysis software, version 8.0 [Bio-Rad Laboratories, München, 
Germany] 
Quantity One® 1D analysis software, version 4.6 [Bio-Rad Laboratories, München, Germany] 
Trans-Blot® SD Semi-Dry Transfer Cell [Bio-Rad Laboratories, München, Germany] 
Typhoon™ Variable Mode Imager 9400 [GE Healthcare, Freiburg, Germany] 
 
Protein identification 
α-Cyano-4-hydroxy cinnamic acid [Sigma-Aldrich, St. Louis, MO, USA] 
Acetonitrile, p.a. [Merck, Darmstadt, Germany] 
Ammonium hydrogen carbonate [Fluka, Sigma-Aldrich, St. Louis, MO, USA] 
Ditihiothreitol [Fluka, Sigma-Aldrich, St. Louis, MO, USA] 
Formaldehyde, p.a. [Fluka, Sigma-Aldrich, St. Louis, MO, USA] 
Iodoacetamide [Fluka, Sigma-Aldrich, St. Louis, MO, USA] 
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Potassium hexacyanoferrate(III), p.a. [Fluka, Sigma-Aldrich, St. Louis, MO, USA] 
Sodium thiosulfate, anhydrous, p.a. [Fluka, Sigma-Aldrich, St. Louis, MO, USA] 
Trifluoroacetic acid [Riedel-de-Haen, Fluka, Sigma-Aldrich, St. Louis, MO, USA] 
Trypsin from bovine pancreas, modified, sequencing grade [Roche Diagnostics, Mannheim, 
Germany] 
ZipTip® C18 Pipette Tips [Millipore, Bedford, MA, USA] 
Equipment 
MALDI TOF/RTOF (AXIMA Tof2TM and CFR™) [Shimadzu Biotech Kratos Analytical, 
Manchester, UK] 
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Methods  
Synthesis of oligonucleotides  
The used anti-bcl-2-siRNA was bought from MWG Biotech [Germany], all other used 
anti-Bcl-2 DNA and RNA oligonucleotide sequences were synthesized on a DNA 
synthesizer according to the phosphoramidite method, which is described in the 
thesis of Winkler [Winkler, 2003]. In brief, the synthesis cycle consists of four 
repeating steps, detritylation (A), coupling (B), capping (C) and oxidation (D), and the 
oligonucleotide is built up from the 3’-end to the 5’-end. Controlled Pore Glass (CPG) 
is used as solid phase. (A) The DMT group of the first CPG-bound nucleotide is split 
off by 3% trichloroacetic acid in dichloromethane (the absorption of the cation is 
measured at 495nm and is used as in-process control in most synthesizers). (B) The 
coupling of the second phosphoramidite is improved by the use of 1H-tetrazole as 
catalyst. (C) Since coupling rates lie between 95 and 100%, an acetylation of 
remaining free 5’-hydroxy-groups is necessary to avoid a further reaction of shorter 
nucleotides. This capping step is done in acetic anhydride in tetrahydrofuran using 
the catalysts N-methylimidazole and 2,6-lutidine. Cap A and Cap B reagents are 
mixed in situ. (D) The oxidation step is performed in iodine/water/pyridine to oxidize 
P(III) to the stable P(V). (E) At the end of the synthesis the solid phase, 
cyanoethylphosphate protecting groups and organic base protecting groups are split 
off by heating the product in concentrated ammonia at 55°C for 16 hours. RNA 
sequences harbor an additional protecting group (t-butyltrimethylsilylester) at the 2’-
end (figure 5), which is stable in concentrated ammonia, but can be removed by 
fluoride ions.  
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Figure 5. RNA phosphoramidite. 
 
Synthesis of phosphorothioates (S-DNA) was performed using 
tetraethylthiuramdisulfide (TETD) as sulfurization reagent, which was recrystallized in 
ethanol before use, and 4,5-dicyanoimidazole (DCI) as activator. Resulting 
phosphorothioates were used as diastereomers, like most of the clinically tested S-
DNAs. Phosporamidites were dissolved 0.05M in water-free acetonitrile and DNA 
oligonucleotides were synthesized in DMT-on mode according to the standard 
procedure described above. RNA sequences were synthesized lacking the last DMT 
group (DMT-off) and heated in a solution of concentrated ammonia and 96% ethanol 
(3:1) at 55°C for 15 minutes. In order to remove the 2`-O-TBDMS-protecting group 
RNA sequences were subsequently stored in tetrabutylammonium fluoride solution 
over night.  
 
Purification of oligonucleotides  
Purification of raw products was performed with SepPak® C18 cartridges. All aqueous 
solutions for DNA purification were prepared with double distilled water (aqua 
purificata). Ammonia solutions containing dissolved S-DNA strands were filtered, 
solvents were evaporated at 40°C and oligonucleotides were resolved in 1M TEAA. 
Cartridges were activated with acetonitrile and equilibrated with 1M TEAA. 
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Subsequently oligonucleotides were repeatedly applied onto the cartridge and 
impurities were washed out with 5% ammonium hydroxide solution and water. After 
detritylation of S-DNA with 2% trifluoroacetic acid (TFA) and removal of remaining 
TFA with water, the pure oligonucleotide was eluated with 30% acetonitrile. Again 
liquids were evaporated and purification was completed by ammonium acetate 
precipitation (20-50µl water, 50µl 7.5M ammonium acetate and ethanol ad 1200µl, 
stored at –20°C for at least 24 hours). Resulting precipitates were centrifuged with 
15000rpm at 4°C for 10min and pellets were resolved in water. Concentrations of 
purified oligonucleotides were determined by UV measurement at 260nm. Molar 
extinction coefficients were calculated as the sum of nucleotides (A, 15400; G, 
11700; C, 7300; T, 8800; U, 9950). 1mM stock solutions were prepared and stored at 
–20°C until used. 
For the purification of RNA sequences RNase-free equipment (heat sterilization of 
used glass ware at 120°C for at least 12hours) and solutions (prepared with RNase-
free water) were used. Distilled water containing 0.1% DEPC was stirred over night 
and subsequently autoclaved to prepare RNase-free water. The elimination of the 2`-
protecting group with TBAF was stopped by addition of the same amount of 1M 
TEAA. Subsequently solvents were evaporated. RNA strands (DMT-off) were 
resolved in 1M TEAA and subsequently desalted with SepPak® C18 cartridges. 
Cartridges were activated with 100% acetonitrile and equilibrated with 1M TEAA. 
RNA oligonucleotides were repeatedly applied to the column, salts were washed out 
with RNase-free water and desalted oligonucleotides were eluated with 30% 
acetonitrile. Ammonium acetate precipitation and concentration determinations were 
performed as described above. 1mM stock solutions were stored at –20°C until used.  
 
 
 42
Materials and Methods 
Quality control of oligonucleotides 
Quality of purified oligonucleotides was controlled by gel electrophoresis and circular 
dichroism.  
Gel electrophoresis:  
RNA and DNA strands were monitored on denaturing 20% polyacrylamide gels 
containing 8M urea. Nucleic acids were mixed with formamide sample buffer (90% 
formamide, 2% 0.5M EDTA, 8% water) and denatured (3min at 95°C, immediately 
cooled on ice). After a pre-run of 30 min in electrophoresis buffer (89mM Tris, 89mM 
boric acid, 4% 0.5mM EDTA) at 200V, samples (1 nM) were run on gels for 90 min at 
the same constant voltage. A mixture of Bromphenol Blue (corresponding to a length 
of 10bp) and Xylene Cyanole (corresponding to a length of 18bp) was used as size 
standard. Oligonucleotide bands were stained with methylene blue (0.1% in sodium-
acetate solution, pH 5.2) for 20min and gel backgrounds were destained with water. 
Pure samples contained only one clearly visible band without shorter or larger 
impurities.  
 
Circular dichroism (CD):  
Oligonucleotide solutions (9µM) were measured in CD buffer (0.15M NaCl, 0.01M 
Tris, pH 7.1) as single and double strands in a quartz cuvette with a pathlength of 
1mm. In the latter case the two complementary single strands were incubated 15 min 
at room temperature before measurement. Instrument parameters were chosen as 
follows: sensitivity: high, scan start: 320nm, scan stop: 200nm, scanning speed: 
20nm/min, data pitch: 0.5nm, band width: 1nm, response: 16sec, accumulation: 3, 
temperature: 20°C. Pure RNA sequences resembled typical A-DNA CD-spectra (C3’-
endo ribose conformation, which is characterized by a distinct positive band with a 
maximum at ~270nm and weaker negative bands at ~235nm and 210nm), whereas 
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pure DNA sequences displayed typical B-DNA spectra (C2’-endo conformation, which 
is characterized by a smaller positive maximum at ~280nm and a stronger negative 
band with a minimum between 245-250nm). For details on CD of nucleic acids see 
Johnson W.C. in: Berova et al., 2000.  
  
Cell culture  
The human melanoma cell line 607B [Thallinger et al., 2007; Jansen et al., 1999] was 
a kind gift from Dr. Wacheck (Medical University of Vienna) and was cultured in 
Dulbecco’s modified Eagle medium supplemented with 10% (v/v) fetal calf serum, 
100U/ml penicillin, 100µg/ml streptomycin, 6mM L-glutamine and 0.25µg/ml 
amphotericin B. 
 
Oligonucleotide transfections and cell lysis  
For oligonucleotide transfections cells were grown on six-well plates (6×105 cells/well, 
uncoated plates) until cells had reached 80% confluence (24 hours after seeding). 
Oligonucleotides were pre-complexed with Lipofectamin2000™ in serum-free 
OptiMem® and transfected to 607B cells 24 and 48 hours after seeding. Four hours 
after each application of oligonucleotide-lipid complexes, serum was added to the 
cells to reach the normal growth media serum concentration. After a total of 72 hours 
the media was removed, cells were washed twice with D-PBS and harvested by 
addition of ice-cold lysis buffer (8M urea, 2M thiourea, 0.5% (v/v) Triton X-100, 2% 
(w/v) CHAPS, 5mM EDTA, 32mM DTT and 1% (v/v) protease inhibitor cocktail). After 
centrifugation (15 000 rpm, 10min, 4°C) to remove cell debris, supernatants were 
collected and total protein concentrations were determined according to Bradford 
[Bradford, 1976].  
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For the Bradford assay samples were mixed with Bradford reagent (0.01% (w/v) 
Coomassie brilliant blue G250, 5% (v/v) ethanol, 10% (v/v) phosphoric acid), 
incubated for 5min at room temperature and measured by spectrophotometry at 
595nm. The protein amount of the samples was calculated by means of a calibration 
curve based on standard bovine serum albumin concentrations (2.5-10µg/ml).  
 
Western blot analysis 
Aliquots of cell lysates containing 20µg of total protein and molecular weight marker 
were resolved by 12.5% SDS-PAGE according to Laemmli [Laemmli, 1970] in 
250mM Tris, 8% (w/v) SDS, 20% (v/v) glycerol, 0.02% (w/v) Bromphenol blue, 
6.2mg/mL DTT after heating the samples for 10min at 95°C. Samples were blotted 
onto PVDF membranes in a semi-dry blotter and unspecific binding was blocked over 
night at 4°C with 1% (w/v) milk powder in TBS buffer containing 0.1% Tween®20 
(0.1% TBST). After four washing cycles with 0.1% TBST à 10min membranes were 
incubated with primary antibodies recognizing either Bcl-2 (1 µg/ml) or actin (0.6 
µg/ml) for 45min at room temperature. Blots were washed again four times à 10min 
with 0.1% TBST and subsequently incubated with HRP-conjugated secondary 
antibodies for one hour at room temperature in the dark. Detection was performed 
using chemiluminescence (ECL Plus). Relative quantification of protein bands was 
done with software–based analysis (Quantity One™ version 4.6.3) after digitalization 
of X-ray films.  
 
Caspase Assay  
Apoptosis is accompanied by a series of characteristic morphological changes. One 
of these intracellular biochemical events is the activation of specific cysteinyl-
aspartic-acid-proteases or short caspases, which play a key role in the further 
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processing of the programmed cell death. Therefore a high caspase activity is related 
to increased apoptosis.  
1×104 607B cells per well were seeded in 96-well fluorescence plates and transfected 
with oligo-lipoplexes as described above. Caspase-3 activity was measured after 24 
hours in a fluorescence plate reader after incubation with DEVD-R110 substrate for 
one hour at 37°C (excitation filter 470-550nm and emission filter 500-560nm).  
 
Annexin-V-FLUOS staining  
Annexin-V is a calcium-dependent phospholipid-binding protein with high affinity to 
phosphatidylserine and is therefore suitable for the detection of apoptotic cells. The 
simultaneous application of Propidium iodide (red), which stains DNA of leaky 
necrotic cells only, allows the discrimination of necrotic cells from the Annexin-V 
(green) positively stained cell clusters [van Engeland et al., 1996].  
1.6×105 607B cells per well were seeded on coverslips in 24-well plates. Cells were 
transfected with oligonucleotide-Lipofectamin2000™ complexes as described above 
and control samples were treated with lipofectamine 2000 alone. After a total of 72 
hours medium was removed, samples were washed one time with D-PBS and 
incubated for 15min at room temperature with Annexin-V-FLUOS labeling solution as 
recommended by the manufacturer. Coverslips were embedded with FluorSave™ 
reagent and analyzed in a Nikon Eclipse 50i microscope equipped with an EXFO X-
Cite 120 fluorescence illumination system. 
Excitation and emission filter blocks were at 465-495/515-555 for green fluorescence 
and at 510-560/>590 for red fluorescence. Pictures were acquired at 20x and 40x 
magnification, respectively, using Lucia Gv5.0 software for image evaluation. 
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Two dimensional gel electrophoresis (2-DE)  
For DIGE gels pH values of cell lysates of treated and untreated samples were 
adjusted to 8.5 using 50mM sodium hydroxide and labeled with CyDye™ Fluor 
minimal dyes according to the manufacturer’s instructions (8pmol dye per µg protein). 
The experimental setup of the DIGE approach is shown in table 3.  
Gel number Cy2 Cy3 Cy5
1 Pooled standard control 1 siRNA 1
2 Pooled standard OBL 1 control 1
3 Pooled standard control 2 OBL 1
4 Pooled standard siRNA 1 control 2
5 Pooled standard siRNA 2 OBL 2
6 Pooled standard OBL 2 siRNA 2
7 Pooled standard OBL 3 control 3
8 Pooled standard siRNA 3 OBL 3
9 Pooled standard control 3 siRNA 3
 
Table 3. Experimental design of the comparison of two antisense agents on the protein level 
using DIGE technology. 
 
In order to compare Oblimersen-treated, siRNA-treated and untreated cells a total of 
nine gels was prepared. Each triplicate corresponded to another biological replicate. 
For the internal standard equal amounts of all samples were pooled and labeled with 
Cy2. Samples were labeled with Cy3 and Cy5. 25µg of labeled samples (Cy3 
labeled), 25µg of labeled samples (Cy5 labeled) and 25µg of internal standard (Cy2 
labeled) were diluted to 350µl with rehydration buffer (8M urea, 4% (w/v) CHAPS, 
13mM DTT and 1% (v/v) pharmalyte 3-11) and applied to 18cm non linear IPG strips. 
Rehydration of the strip/sample application was performed for 12 hours at 20°C. 
Isoelectric focusing was carried out to a total of 80kVhr on an IPGphor unit. The 
focused IPG strips were reduced 15min (1% DTT (w/v)) and alkylated 15min (2.5% 
iodoacetamide) in equilibration buffer (50mM Tris-HCl, 6M urea, 30% (v/v) glycerol, 
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2% (w/v) SDS, a few grains of Bromphenol blue, pH 8.8). The second dimension was 
performed on homogenous 12.5% polyacrylamide gels (20x22cm) applying constant 
50mA per gel. All gels were scanned at 100µm resolution on a Typhoon 9400 imager 
and analyzed with DeCyder software version 6.5.  
2-DE experiments for silver, Coomassie and Sypro Ruby staining were carried out as 
described above lacking the labeling process (rehydration solution: 8M urea, 2M 
thiourea, 4% (w/v) CHAPS, 0.5% (v/v) Triton X-100, 0.005% Bromphenol blue, 32mM 
DTT and 0.5% pharmalyte; equilibration solution: 50mM Tris-HCl, pH 8.8, 6M urea, 
30% (v/v) glycerol, 2% (w/v) SDS and a few grains of Bromphenol blue).  
Instrument parameters for isoelectric focusing with IPG strips of different pI are 
summarized in table 4.  
pI 3-11  4-7 6-9 
 rehydration 12hours 
20°C 
rehydration 12hours 
20°C 
rehydration 12hours 
20°C 
Step 1 gradient 500V,  
300Vhr 
gradient 500V,  
300Vhr 
step 500V, 
500Vhr 
Step 2 gradient 1000V, 
750Vhr 
gradient 1000V, 
750Vhr 
gradient 1000V, 
800Vhr 
Step 3 gradient 2000V,  
1500Vhr 
gradient 2000V,  
1500Vhr 
gradient 10 000V,  
16 500Vhr 
Step 4 gradient 4000V,  
2000Vhr 
gradient 4000V,  
2000Vhr 
step-n-hold 10 000V,  
50 000Vhr 
Step 5 gradient 8000V, 
6000Vhr 
gradient 8000V, 
6000Vhr 
step-n-hold 5000V, 
5h 
Step 6 step-n-hold 8000V, 
73200Vhr 
step-n-hold 8000V, 
73200Vhr 
 
Step 7 step-n-hold 2000V,  
5 h 
step-n-hold 2000V,  
5 h 
 
  
Table 4. Summary of isoelectric focusing parameters. 
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2-DE gels were post-stained with Coomassie R-250 or silver according to Blum or 
Shevchenko, respectively [Blum, 1987; Shevchenko, 1996]. Briefly, silver staining 
according to Blum included a fixation step (over night in 10% (v/v) acetic acid, 40% 
(v/v) methanol), two washing steps à 20min with 30% (v/v) ethanol and one with 
water, followed by a sensitization step (1min in 200mg/l sodium thiosulfate), the 
incubation in silver solution (30min in 0.02% (v/v) formaldehyde, 2g/l silver nitrate) 
and a developing step (30g/l sodium carbonate, 5mg/l sodium thiosulfate, 0.05% 
formaldehyde). Staining was stopped by addition of a glycine solution (5g/l glycine). 
The second silver staining method, which was better compatible with subsequent MS 
experiments, started with a fixation step (20min in 50% (v/v) methanol, 5% (v/v) 
acetic acid), a washing step in 50% (v/v) methanol and one in water, followed by a 
sensitization step (1min in 200mg/l sodium thiosulfate), two short washing steps in 
water, the incubation in silver solution (1g/l silver nitrate), a short washing step in 
water and the developing step (20g/l sodium carbonate, 0.04% (v/v) formaldehyde). 
Staining was stopped with a solution containing 5% (v/v) acetic acid and gel 
backgrounds were washed with water. Wet gels were digitized at 85µm resolution 
using the densitometer GS-710.  
For Coomassie R-250 standard staining gels were fixed for one hour in a fixing 
solution (45% (v/v) methanol, 5% (v/v) acetic acid), washed two times with water and 
incubated with the staining solution (0.025% (v/v) Coomassie Brilliant Blue R-250, 
40% (v/v) methanol, 7% (v/v) acetic acid) until blue protein bands were visible. 
Subsequently gel backgrounds were destained in two steps: 30min destaining 
solution I (40% (v/v) methanol, 7% (v/v) acetic acid), ~1 hour destaining solution II 
(7% (v/v) acetic acid, 5% (v/v) methanol) until backgrounds were clear. Coomassie-
stained gels were digitized using the densitometer GS-710, using the integrated 
Coomassie Blue filter.  
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SYPRO® Ruby post-staining included a fixation step (30min, 10% (v/v) methanol, 7% 
(v/v) acetic acid), the light-protected incubation with SYPRO® Ruby (over night at 
room temperature using 250ml for 2 gels) and a background-destaining step (30min, 
10% (v/v) methanol, 7% (v/v) acetic acid) as well as two washing steps in water 
afterwards. Wet gels were imaged with a CCD-based ChemiDoc XRS imager at a 
resolution of ~150µm using the integrated filter for fluorescence imaging.  
 
Software-based image analysis 
Silver-, Coomassie and Sypro Ruby-stained 2-DE gels were analyzed with the 
software tool PD-Quest (Bio-Rad; version 6.1 and 8.0, respectively), whereas DIGE 
gels were evaluated using the software package DeCyder (GE Healthcare, version 
6.5). The image analysis process with PD-Quest was performed using the spot 
detection wizard provided by the software and is described in Stessl et al., 2009. In 
brief, raw gel files were cropped and classified into replicate groups. A parameter set 
including sensitivity, size scale and minimal peak height was chosen according to the 
appearance of respectively stained gels. Speckle and streak filters were applied and 
all gels were warped before analysis. Spot detection was performed automatically 
excluding all saturated spots from further evaluation. Spot matching was performed 
either on the basis of the selection of landmark spots (version 6.1) or automatically 
(version 8.0). In both cases all matched spots were subjected to a careful manual 
control with regard to spot positions and match quality. In order to compensate for 
non-expression-related variations in spot intensities, normalization was performed 
using the recommended standard procedures by the respective software version 
(“total density on gel” version 6.1; “local regression model”, version 8.0). For further 
quantitative and statistical analyses only appropriately matched spots with a 
satisfying spot quality (a parameter including accuracy of Gaussian fitting, horizontal 
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and vertical streaking, spot overlap and linearity) were included (for silver stained 
gels the minimum spot quality was assumed with 60 according to Schlags et al., 
2005).  
 
DIGE image evaluation with DeCyder included two major steps of cropped raw 
images (DIA: differential analysis module, BVA: biological variation module) and was 
based on volume ratios (sample spot volume divided by the corresponding internal 
standard spot volume). Since differences between Cy3- and Cy5-labeled proteins 
have been reported [Tonge et al., 2001] only Cy3-labeled samples and Cy2-labeled 
internal standards were taken into consideration for further quantitative analyses. The 
following DIA module parameters were chosen: number of estimated spots: 2500, 
exclusion filter (volume<75000 and slope>1.7), whereupon all excluded spots were 
manually controlled for eventual false exclusions. Remaining spots were normalized 
[for details on the automatic normalization process performed by DeCyder see 
Winkler W et al., 2008], grouped and exported to the BVA module, where the 
matching process was performed. ~75 well resolved spots from different gel regions 
(corresponding to 8.5% of all included spots), which were present in all gel maps, 
were defined as landmark proteins to facilitate the matching process. After manual 
control and matching confirmation, proteins of interest were defined, including only 
spots passing the following criteria: average ratio ±1.5, Student’s t-test (p≤0.05), 1-
way ANOVA (p≥0 and ≤0.05), appearance in at least 16 of 18 spot maps and match 
quality <6. The match quality is a value calculated by the software from the surface 
profiles of each internal standard on each gel matched to the master spot maps, 
ranging from 0 (very good) to 15 (very bad). The raw data of interesting spots were 
exported to Microsoft Excel 97 using the DeCyder XML tool. Afterwards gels were 
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post-stained with silver nitrate according to Shevchenko [Shevchenko, 1996] and 
stored in water at room temperature until protein identification. 
 
Protein identification by mass spectrometry 
The theory about the used mass spectrometric method (matrix-assisted laser 
desorption/ionization reflectron time-of-flight mass spectrometry (MALDI-rTOF-MS)) 
is summarized in supplement A of this thesis. Identification of proteins was performed 
as described in [Stessl et al., 2009]. Spots of interest were cut out manually from 2-
DE gels and subjected to in-gel digestion using trypsin. Desalted and purified 
samples (ZipTip C18) were measured in positive reflectron mode by MALDI-rTOF MS 
(MALDI Tof² and CFR± instrument, respectively) using α-cyano-4-hydroxycinnamic 
acid as matrix. Both thin layer and dried droplet sample preparation techniques [Vorm 
et al., 1994] were used. External calibration was performed using singly charged 
monoisotopic m/z values of standard peptides (bradykinin fragment 1-7, human 
angiotensin II, angiotensin I, glu-1-fibrinogen peptide, N-acetyl renin substrate and 
ACTH fragments). Unsmoothed PMF were manually reviewed using the Shimadzu 
Biotech Kratos Analytical software (Launchpad, version 2.7.1) and monoisotopic m/z 
values were listed excluding peaks belonging to tryptic auto-digestion, keratins 
[Mattow et al., 2004] or matrix ion-clusters [Smirnov et al., 2004]. The publicly 
available search engines MASCOT (Revision 2.1.0) [Perkins et al., 1999] and 
ProFound [Zhang et al., 2000] were used to search different databases: SwissProt 
(MSDB (version 50.6 of 2006-09-05 to 54.5 of 2007-11-04) and the non redundant 
NCBI (Sequence Release 19 of 2006-09-10 to 26 of 2007-11-13) databases. Search 
criteria: fixed modification (carbamidomethylation of cysteins), variable modification 
(oxidation of methionins), taxonomy (H. sapiens), missed tryptic cleavages (1), m/z 
tolerance (±50 mDa), molecular weights (±20Da, ProFound only) and isoelectric 
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points estimated from 2-D gels (±2, ProFound only). Protein identification was further 
confirmed by post source decay (PSD) and MS/MS experiments of selected peptides 
on the above mentioned instruments. The fragment ion m/z values were exported 
from smoothed spectra (Savitsky Golay algorithm [Savitzky et al., 1964]). MS/MS 
database search was performed using average peptide fragment ion masses with the 
same restrictions as for PMF, additionally a product ion tolerance of ±1 Da was 
defined. A hit was considered to be significant, if the scores obtained for PMF and 
MS/MS data clearly exceeded each algorithm's significance threshold (p<0.05).  
Protein accession numbers mentioned in the text and tables can be found in the 
publicly available database SwissProt at www.expasy.org.  
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Results  
1. Oligonucleotides  
One main focus of this work was the investigation of specific and unspecific effects of 
the 18-mer phosphorothioate (S-DNA) Oblimersen (Genasense, G-3139), which is 
directed against the first six codons of the human bcl-2 mRNA. The following control 
sequences for cell culture experiments were used: (1) the antiparallel, 
complementary sense sequence, (2) a scrambled sequence (containing the same 
number of organic bases as the original antisense sequence but in randomly chosen 
order) and (3) a mismatch sequence harboring thymidine instead of guanine at 
position eight. Similar control sequences were prepared for respective anti-bcl-2 
siRNA sequences. An overview of the DNA and RNA oligonucleotide sequences for 
the present work is given in table 5.  
 Sequence (5‘-3‘)
 
Table 5. Summary of synthesized DNA and RNA oligonucleotide sequences. Sequences 
were taken from denoted references. 
 Target Reference 
S-DNA:    
Oblimersen (G 3139) antisense TCT-CCC-AGC-GTG-CGC-CAT bcl-2 Tarhini et al (2007) 
Oblimersen sense ATG-GCG-CAC-GCT-GGG-AGA   
Oblimersen scrambled (control) GAG-TCT-ACC-GTC-CCT-GCC   
Oblimersen 1base mm (control)  TCT-CCC-ATC-GTG-CGC-CAT   
si RNA     
Anti-Bcl-2-siRNA antisense UGU-GGA-UGA-CUG-AGU-ACC-UAG-dTdT bcl-2 Wacheck et al (2003) 
 sense UCA-GGU-ACU-CAG-UCA-UCC-ACA-dTdT   
Anti-Bcl-2-siRNA scrambled (control) AUU-CGC-ACU-CGC-ACU-CGA-AUA-dTdT   
Anti-Bcl-2-siRNA 3 base mm (control) UGU-AGA-UGA-CUU-AGU-ACG-UGA-dTdT   
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2. Influence on target protein expression  
The human melanoma cell line 607B was used for performed cell culture 
experiments. 607B cells over-express the target protein Bcl-2 [Thallinger et al., 2007; 
Jansen et al., 1999]. Preliminary experiments were performed to optimize 
oligonucleotide transfection conditions. Working concentrations leading to the same 
level of target protein inhibition were determined. Inhibitions of Bcl-2 expression 
levels are shown in table 6 and figure 6 and 7.  
 
 
 
Sequence [nM] 
 
Obl    50 
 
Obl  100 
 
Obl  150 
 
Obl  200 
 
siRNA    5 
 
siRNA  10 
 
siRNA  15 
 
siRNA  25 
 
siRNA  50 
 
siRNA 100 
Bcl-2 inhibition [%] *
 
46 ± 5.81 
 
75 ± 4.89 
 
65 ± 4.89 
 
59  
 
78 ± 2.98 
 
80 ± 2.48 
 
80  
 
82 ± 4.29 
 
75 ± 5.70 
 
80 ± 1.49 
Table 6. % Bcl-2 inhibition achieved with different concentrations of Oblimersen (Obl) and 
anti-bcl-2-siRNA (siRNA). * Values were calculated with QuantityOne® software as means of 
triplicates. Treated samples were referred to untreated controls (100% target protein) and 
normalized on the expression of actin as loading control.  
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Figure 6. Illustrations of target inhibition by four different concentrations of Oblimersen (Obl; 
left) and anti-bcl-2-siRNA (siRNA; right). Values were referred to untreated controls and 
normalized on expression levels of actin. 
 
In accordance with literature the phosphorothioate had to be applied in higher 
concentrations than the respective siRNA to monitor any influence on target protein 
expression [Anderson et al., 2006; Wacheck et al., 2003]. For Oblimersen a minimum 
concentration of 50 nM was necessary to achieve 46% of down-regulation – below 
that, no significant regulation could be observed. The maximum Bcl-2 expression 
inhibition of 75% could be achieved at 100 nM. This concentration was therefore 
chosen as Oblimersen working concentration. Higher phosphorothioate 
concentrations (150 nM, 200 nM) again resulted in lower inhibition levels of 65% and 
59%, respectively. 
The chosen siRNA sequence was more effective in target protein down-regulation 
than the phosphorothioate - even in very low concentrations of 5 nM or 10 nM Bcl-2 
expression levels could be reduced for ~80%. Since a concentration of 50 nM 
achieved the same 75% of target protein inhibition compared to Oblimersen, this 
concentration was chosen as corresponding siRNA working concentration. 
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Denoted control sequences (scrambled and mismatch-containing sequences) did not 
show any target protein knockdown under the same experimental conditions. As 
shown in table 7 the combination of the two antisense agents did not lead to a 
significant increase of protein knockdown compared to siRNA alone.  
 
 
 
 
Combinations 
 
Obl 50nM + siRNA 25nM 
 
Obl 50nM + siRNA 50nM 
 
Obl 100nM + siRNA 10nM 
 
Obl 100nM + siRNA 50nM 
Bcl-2 inhibition [%]
 
73 
 
79 
 
68 
 
85 
Table 7. Bcl-2 inhibition levels achieved by combinations of Oblimersen (Obl) and anti-Bcl-2 
siRNA (siRNA). Standard deviations are not available (n.a.) since these transfections were 
only performed once. 
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42kDa, actin
26kDa, Bcl-2
Anti-Bcl2-siRNA Lipof.siRNA contr. Contr.
42kDa, actin
26kDa, Bcl-2
Oblimersen (O) Lipof. Contr.O mismO sense  
Figure 7. Western blot analyses demonstrating effective Bcl-2 down-regulation by antisense 
(Oblimersen) and anti-Bcl-2-siRNA. Total proteins were extracted after 72 h and protein 
levels were assessed by Western blotting using protein specific antibodies. Lipof., unloaded 
lipofectamine2000, Oblimersen or O, Oblimersen [100 nM] transfected with 
lipofectamine2000 (representative duplicate), siRNA, anti-Bcl-2-siRNA [50 nM] transfected 
with lipofectamine2000 (representative duplicate), O mism., Oblimersen with 3 mismatches, 
siRNA contr., scrambled siRNA sequence, Contr., untreated cells. Equal gel loading was 
controlled by actin expression.  
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3. Apoptosis induction  
For oligonucleotide transfections 607B cells were seeded in 6-well plates and grown 
to nearly confluent monolayers. After 48 hours Oblimersen-treated 607B cells 
showed a significant loss of adhesion from cell culture plates, indicating a high level 
of cell death. Cell layers transfected with siRNA, however, did not show any 
significant differences from untreated cells and cell layers were still intact (figure 8). 
 
A B C
 
Figure 8. 607B cell layers after respective oligonucleotide transfections. 6×105 cells/well were 
seeded in 6-well plates and monitored in the light microscope after 48 hours. A: Obl-treated 
cells, B: siRNA-treated cells, C: untreated cells. 
 
It has been previously described that Oblimersen and bcl-2-targeted siRNAs are not 
equivalent as apoptotic/cytostatic agents and that they induce disparate phenotypes 
in PC3 and LNCaP prostate cancer cells [Anderson et al., 2006]. Therefore, the 
levels of oligonucleotide-induced apoptosis were investigated on 607B melanoma 
cells. Based on an equal Bcl-2 protein down-regulation of 75%, apoptotic state and 
caspase-3 activity after phosphorothioate and siRNA treatment were monitored with 
respective assays (figure 9 and 10).  
After Oblimersen treatment a significantly higher number of apoptotic cells (green, 
Annexin-V-Fluorescein-stained) could be detected compared to anti-bcl-2-siRNA-
treated and untreated cells (figure 9). Therefore it can be stated that Oblimersen 
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treatment clearly induced apoptosis in 607B melanoma cells, whereas no significant 
increase in Annexin-V-stained apoptotic cells could be detected in siRNA-treated and 
control cells. None of both treatments did induce necrosis, since no significant 
number of necrotic cells (red, Probidium iodide-stained) could be detected.  
(A)
(B)
(C)
 
Figure 9. Fluorescence images of melanoma cells show apoptosis induction in Oblimersen-
treated (A) but not in siRNA-treated (B) or control cells (C). Apoptotic cells were detected 
with annexin-V-fluorescein (left panel) and necrotic cells are stained with Probidium iodide 
(right panel). 
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Additionally a higher level of caspase-3 activity was detected in 607B cells after 
Oblimersen treatment (+30%) compared to siRNA application and control (figure 10).  
 
 
 
Figure 10. Evaluation of apoptosis induction reflected by increase of caspase-3 activity 
induced by respective treatments. The untreated control was set to 0%.  
*: p<0.05 compared to untreated control. 
 
Gene profiling studies of Oblimersen and Bcl-2-targeting siRNAs [Anderson et al., 
2006] revealed an additional involvement of various genes in the mechanism of 
action of Oblimersen. Since the effects on the genome and the proteome are not 
necessarily the same and even siRNA-sequences have been reported to have 
varying off-target effects [Jackson et al., 2003], the present study focused on the 
quantitative elucidation of off-target effects of Oblimersen and the anti-Bcl-2 siRNA 
on the proteome using DIGE technology. 
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4. Proteomic investigation  
4.1 Two-dimensional separation and staining conditions 
The measurement of quantitative changes in protein expression upon a special 
treatment deserves a careful selection of the appropriate method providing reliable 
and significant information. Two-dimensional spot patterns can be visualized in 
different ways, including staining after the separation with dyes such as silver nitrate 
[Shevchenko et al., 1996], Coomassie Brilliant Blue [Fievet et al., 2004], Sypro Ruby 
[Smejkal et al., 2004] or by pre-labeling of samples prior to separation with 
fluorescence [Ünlü et al., 1997; Minden, 2007]. For various biological questions and 
sample types, however, used two-dimensional gel electrophoresis (2-DE) [O’Farrell, 
1975] conditions and analytical parameters have to be carefully optimized in terms of 
sensitivity, linear dynamic range, reproducibility, compatibility with mass spectrometry 
and easiness of handling.  
 
For the separation of 607B cell lysates ImmobilineTM DryStrip gels ranging from pI 3-
11 NL and an acrylamide concentration of 12.5% were chosen. Under these 
prerequisites an optimal resolution could be achieved and the highest number of 
protein spots (averagely 2500-3000) could be monitored on one gel.  
Figures 11-14 demonstrate two-dimensional gels of untreated melanoma cell lysates 
stained with Coomassie Brilliant Blue R-250 (figure 11), silver nitrate (figure 12), 
SYPRO® Ruby (figure 13) and CyDyes™ (figure 14).  
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Figure 11. Two-dimensional gel image of 607B cell lysate, 75µg of total protein, pI 3-11 NL, 
stained with Coomassie Brilliant Blue R-250. 
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Figure 12. Two-dimensional gel image of 607B cell lysate, 75µg of total protein, pI 3-11 NL, 
stained with silver nitrate according to Blum [Blum et al., 1987]. 
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Figure 13. Two-dimensional gel image of 607B cell lysate, 75µg of total protein, pI 3-11 NL, 
stained with SYPRO® Ruby (left panel: original image; right panel: inverted data).  
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Figure 14. DIGE image of 607B cell lysate (overlay of all three channels), 75µg of total 
protein, pI 3-11 NL (left panel: original image; right panel: inverted data). 
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Coomassie Brilliant Blue (CBB) R-250 staining was easy to perform and excised 
protein spots could be directly used for subsequent in-gel digestion and mass 
spectrometry (MS) measurements. Approximately only two third of the overall 
number of protein spots, however, could be detected with CBB compared to the other 
staining protocols used. CBB-stained two-dimensional gels were therefore only used 
for preliminary MS experiments. 
 
On silver stained gels an average number of 2700 spots could be detected, which 
was approximately one third more than on CBB stained gels. The four-step protocol 
consisting of fixation, sensitization, silver impregnation and development is relatively 
easy to perform, but - even if staining times and conditions were exactly kept – high 
inter-gel variations were observed. During software-based image analysis many 
saturated spots were detected, which had to be excluded from quantitative analysis. 
For subsequent in-gel digestion and MS experiments, excised protein spots had to be 
destained [50:50 aqueous solution of 100 mM sodium thiosulfate and 30 mM 
potassium hexacyanoferrate[III] according to Blum, 1987] in order to get pure MS 
spectra. Due to the low dynamic and linear range of silver staining [Westermeier et 
al., 2005] this method is not reliable for quantification. Taking advantage of the high 
sensitivity, silver staining was only used for qualitative gels. 
 
With the fluorescent dye SYPRO® Ruby a similar sensitivity compared to silver 
staining protocols was achieved - on average 2500-2700 spots could be detected for 
separated 607B cell lysates. Gel backgrounds were clear and the handling was 
rather easy. The wide linear and dynamic range (over four orders of magnitude) 
[Miller et al., 2006] made it very suitable for subsequent image analysis. Since the 
 65
Results 
staining with fluorescent dyes is an endpoint method [Miller et al., 2006], no over-
staining or saturation of protein spots was observed. SYPRO® Ruby stained proteins 
could be directly subjected to in-gel digestion and MS measurements. In brief, this 
staining method represented the best of all used post-staining protocols.  
 
The method of choice for the quantitative comparison of treated and untreated 607B 
cell lysates was given by the Difference Gel Electrophoresis (DIGE) technology [Ünlü 
et al., 1997; Sitek et al., 2006]. Treated and untreated samples were labeled with 
different CyDyes™ prior to electrophoresis and an internal standard was included 
into the approach according to the scheme in figure 15. Since these dyes are 
structurally similar but spectrally quite distinct, the method allows multiplexing, that 
means the separation of two to three complex protein samples – each labeled with 
another dye – on the very same gel.  
 
 
Figure 15. Schematic representation of a DIGE workflow [picture taken from Westermeier et 
al., 2005]. 
 
 66
Results 
Gels were scanned at three different wavelengths corresponding to the dyes used – 
so on one gel three samples could be run and fewer gels had to be done compared 
to post-staining techniques. Inter-gel variations resulting from experimental handling 
could be excluded leading to highly reliable quantitative data. With the help of the 
protein pattern created by the internal standard, other sample patterns could be more 
easily matched and each sample spot volume could be normalized to the standard 
spot volume. Consequently, protein expression changes of ±1.5 fold were considered 
to be relevant. Although the received sensitivity was lower compared to silver staining 
– on average ~2000 spots could be detected -, most of the spots were better 
resolved and fewer “shine-spots”, id est speckles and impurities, were detected. 
Therefore fewer spots had to be excluded from statistical analysis. For the used 
“minimal labeling” the dye/protein ratio is kept at average 3/100 - so it is ensured that 
only one single lysine residue in each protein is labeled. Since the dyes are charge-
matched, the pI of investigated proteins is supposed to stay constant upon labeling. 
The molecular mass of the labeled protein slightly differs from the unlabeled protein 
(about 0.5kDa, equal for each dye [Alban et al., 2003]) and so does the pI. Therefore 
all gels had to be post-stained with silver for subsequent in-gel digestion and MS 
measurements. 
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4.2 Establishment of a protein reference map of 607B cells 
For all proteomic investigations cells from the same batch were used (ranging from 
passage 90 to passage 180). As a first step the used cell line 607B was 
characterized on the protein level by the establishment of a protein reference map. 
Most abundant spots as well as spots from varying pI and molecular weight sections 
of the gel were identified. Figure 16 gives an overview of identified reference 
proteins.  
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Figure 16. Established protein reference map of 607B cells. Positions of identified reference 
proteins are indicated with yellow boxes. 
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Mass spectrometric data of reference proteins 
All proteins were subjected to tryptic in-gel digestion and unambiguously identified by 
subsequent matrix-assisted laser desorption/ionization reflectron time-of-flight mass 
spectrometry (MALDI-rTOF-MS) (peptide mass fingerprinting (PMF) in combination 
with post source decay (PSD) experiments for selected tryptic peptides) as described 
under Materials and Methods. Representative PMF spectra with m/z value lists and 
MS/MS graphs are presented in supplement A (figure A-S). Detailed information 
about identified reference proteins are summarized in table 8, including PMF and 
PSD scores, sequence coverage, the number of matched peptides, pI, molecular 
weight and peptide sequences of precursor ions used for PSD. Data for the proteins 
actin (ACTB), cofilin-1 (COF-1), enolase-1 (ENOA-1), galectin-1 (LEG-1), 
phosphoglycerate mutase (PGAM) and triosephosphatisomerase (TPIS) are 
presented in supplement B, since they have been found to be differentially expressed 
after Oblimersen treatment.  
 
For in-gel digestion trypsin from bovine pancreas [Roche] was used. The following 
monoisotopic m/z values resulting from tryptic auto-digestion were experimentally 
obtained: 659.55, 805.60, 906.67, 1153.77, 2163.22, 2273.93 and 2611.96. These 
m/z values were used to check calibration for accuracy.  
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Table 8. Identified landmark protein species present in 607B melanoma cells.  
Protein name Acc. number pI theor. MW [kDa] PMF Score* Sequ. Cov [%] 
Matching 
  peptides**
PSD Peptide sequences Score*** 
AHA-1  O95433 5.4 38.27 126 30 12 (18) 1484.6; 1714.7 ETFLTSPEELYR; ADATNVNNWHWTER 187 (38) 
TCP zeta P40227 6.25 58.31 124 33 17 (29) 758.0; 938.5; 1499.5 EGIVALR; GLVLDHGAR; QADLYISEGLHPR 175 (39) 
EF-2 P13639 6.42 96.12 104 16 16 (22) 970.0 GGGQIIPTAR 22 (39) 
GADPH P04406 8.58 36.05 68 21 8 (15) 1764.3 LISWYDNEFGYSNR 87 (38) 
H+ATPase lyso P15313 5.57 56.82 100 22 15 (23) 1309.8 NFIAQGPYENR 90 (39) 
HSP-70 P11142 5.28 70.90 194 36 23 (32) 1200.3 DAGTIAGLNVLR 57 (36) 
HSP-90 P07900 4.94 84.88 102 19 17 (25) 730.8; 1195.6 LSELLR; IDIIPNPQER 69 (40) 
LDH P00338 5.71 36.90 52 14 5 (9) 743.0; 914.5 LNLVQR; IVVVTAGVR 50 (39) 
Mortalin P38646 5.87 73.68 106 24 16 (26) 1362.5 AQFEGIVTDLIR 73 (36) 
NDK A P15531 5.42 19.87 70 38 7 (10) 1052.5; 1345.4 GDFCIQVGR; TFIAIKPDGVQR 85 (39) 
PDIA6 Q15084 4.95 48.12 145 35 13 (18) 1528.7 LAAVDATVNQVLASR 42 (38) 
Progerin Q6UYC3 6.22 69.49 96 21 15 (25)  -   -  -  
PSA-3 P25788 5.19 28.51 101 33 9 (15) 1579.3 SLADIAREEASNFR 24 (38) 
PURH P31939 6.39 64.94 128 25 14 (19)  -   -  -  
STIP-1 P31948 7.81 68.67 55 13 12 (26) 1465.8;  LDPHNHVLYSNR 62 (38) 
SYYC P54577 6.61 59.49 132 25 16 (21) 1059.7; 1206.7 EYTLDVYR; VDAQFGGIDQR 68 (40) 
Tubulin β P07437 4.71 49.67 222 66  1039.4; 1131.61; 2799.8 YLTVAAVFR; FPGQLNADLR; 
SGPFGQIFRPDNFVFGQSGAGNNWAK 
135 (38) 
Ubiquitin P62988 5.73 8.12 189 97 11 (16) 1039.4 EGIPPDQQR 22 (39) 
Vimentin P08670 5.06 53.65 242 46 26 (32) 1295.6; 1571.7 MALDIEIATYR; ISLPLPNFSSLNLR 118 (38) 
* Protein scores greater than 64 are significant (p<0.05). ** Number of unmatched peaks is given in brackets. *** Ion scores greater than the number given in brackets are significant (p<0.05). 
AHA, activator of 90 kDa ATPase homolog, EF, elongation factor, GADPH, glyceraldehyde-3-phosphate dehydrogenase, LDH, L-lactate dehydrogenase, NDK, nucleoside diphosphate 
kinase, PSA, proteasome subunit alpha, PURH, bifunctional purine biosynthesis protein, STIP, stress-induced-phosphoprotein, SYYC, tyrosyl-tRNA synthetase. 
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Figure 17. Scheme outlining the PD-Quest based 2-DE image analysis process. For a 
detailed description of image analysis with PD-Quest see Marengo et al., 2005. 
During this thesis the available image analysis software PD-Quest™ version 6.1 [Bio-
Rad Laboratories] of the laboratory was equipped with the update version 8.0 and the 
question arose whether a different software or software version, respectively, would 
lead to different quantitative results for the same 2D-gel set. Two replicate gel groups 
(Oblimersen-treated versus untreated) were prepared, cropped (pI ~4-8) to simplify 
the process and independently analysed with PD-Quest™ version 6.1, PD-Quest™ 
version 8.0 and Delta 2D [Decodon] version 6.5 [Stessl et al., 2009]. 
4.3 Influence of image-analysis software on quantitation of 2-DE data  
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Results 
Figure 17 represents a simplified scheme of the image-analysis process with the two 
mentioned versions of PD-Quest. The analysis with Delta 2D was performed 
externally by Markus Kolbe [Decodon].  
Using a defined parameter set and the same two-dimensional gel set, 876 (control 
group) and 989 (treated group) protein spots, respectively, remained in the data set 
with version 6.1. 1041 (control group) and 978 (treated group) protein spots, 
respectively, passed the criteria for being included in quantitative analyses with 
version 8.0 (table 9 A). The number of detected spots was reproducible with both 
versions.  
Matching capabilities of image-analysis software are strongly influenced by gel and 
spot quality. Therefore used gels were critically reviewed for their reproducibility. 
Table 9 B shows spot qualities and CV values calculated among biological replicates 
of ten randomly selected spots from different pI and MW areas. According to Schlags 
[Schlags et al., 2005] the quantitative repeatability for silver-stained replicates is 
given if RSD values (relative standard deviation or coefficient of variance [CV]) are 
below 30% and the spot quality of included spots (optical density, defined as 
[INT*mm²]) is beyond a value of 60.  
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A  
Spot number CV [%] treated CV [%] untreated Spot quality 
1 24.93 23.52 82
2 13.19 19.13 86
3 16.63 1.61 93
4 16.86 13.31 89
5 20.27 11.88 70
6 1.10 12.12 97
7 15.02 26.46 80
8 4.84 9.05 74
9 11.62 7.12 90
10 8.76 0.79 93
Replicate version 6.1 version 8.0
group Mean SD CV(%) Mean SD CV(%)
Control 876 137 15.6 1041 204 19.6
Treated 989 89 9.0 978 47 4.8
 
B
Table 9 A. The total number of detected spots is reproducible with both software versions. B. 
Spot qualities (mean of triplicates) and CV values calculated among biological replicates of 
ten randomly chosen spots are presented. If CV values are below 30%, spots are considered 
as reproducible. 
 
 
In version 6.1 the matching process is based on the selection of reference spots, 
therefore ten well-resolved spots (table 9 B) were chosen as landmarks. Version 8.0 
provides automatic matching. Nevertheless, in both cases all matched spots were 
subjected to a careful manual control with regard to spot positions. Only 
semiautomatic tools (“delete, add, manual match and unmatch”) were used to 
minimize the operator’s influence on the study. Thereby the newly introduced group 
consensus tool of version 8.0 was very helpful to find spot matching errors among 
replicates.  
Differentially expressed proteins were determined by their differences in the 
corresponding gel-spot volumes between control and treated sample. Generally this 
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difference is determined by a volume ratio, whereupon a factor of 2 corresponds to 
100% variation. The chosen threshold level is based on the quality of the gel, 
reflected by the total variance among replicates and the staining method used for 
spot visualization. The treshold represents a sensitive variable ruling over in- or 
exclusion of spots in a quantitative analysis set. In this study, spots showing a fold-
change of at least 2 meeting the criteria of a statistical Student’s t-test (significance 
level of 90%) were considered as differentially expressed. Volume ratios of ten spots 
(figure 18) were calculated using the mean values of exported normalized spot 
volumes provided by the respective software (table 10).  
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Figure 18. 75µg of total protein were separated on a 3-11 NL IPG strip, 12.5% SDS-PAGE, 
silver-stained. The zoomed area shows the gel part that was taken for image analysis. 
Arrows and numbers indicate the ten spots, which were investigated for their volume ratios. 
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Spot number PDQ version 6.1 PDQ version 8.0 Delta 2D version 3.6
I 1.46 1.91 1.30
II 2.18 1.64 1.14
III 2.56 1.81 1.02
IV 1.68 1.92 1.36
V 1.42 1.98 1.49
VI 1.82 2.00 1.48
VII 2.97 2.45 2.29
VIII 2.40 2.21 1.32
IX 2.31 2.10 1.27
X 1.87 1.96 1.29
 
Table 10. Calculated factors reflecting the volume ratios of treated versus untreated or vice 
versa, respectively, based on normalized spot volumes exported from the different software 
packages.  
 
 
Figure 19. Venn diagram illustrating the detection of differentially expressed (± 2 fold-
changes) spots from table 10 by respective software packages. Factors 1.98 and 1.96 (spots 
V and X) were included. 
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A Venn diagram (figure 19) visualizes differences and overlaps for the chosen gel 
spots. Under the chosen quantitative conditions (fold-change of at least ±2 AND 
meeting a Student’s t-test p<0.10) only one spot (VII) was detected as differentially 
expressed with all three software packages (figure 19) and is therefore placed in 
overlapping circles. Spot VII is also the only spot showing a fold change of >2 after 
analysis with Delta 2D. Two additional spots (VIII and IX) met the criteria with both 
PD-Quest versions, but not with Delta 2D. All other spots were only detected as 
differentially expressed by one of the three software packages. Spot II and III were 
found to be significantly changed with PDQ version 6.1, but were not part of a 
quantitative analysis set after evaluation with PDQ 8.0 and Delta 2D. Spot VI (and V), 
however, is (were) found as changed with PDQ 8.0, but no significant difference 
could be detected with PDQ 6.1 or Delta 2D. No general tendency of in- or 
decreasing volume ratios was observed during the comparison of volume ratios with 
the three tools, each spot had to be controlled individually. Since the same digital 
images were included in all three evaluations and important analysis parameters 
were kept constant (figure 17), obtained results point out that - beside the variance 
introduced by experimental procedures - software-related variations are another 
important reason why 2-DE data are not directly comparable to each other [Stessl et 
al., 2009].  
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4.4 DIGE-based off-target effect study  
 
The DIGE-based proteomic approach for the comparison of off-target effects of the 
phosphorothioate Oblimersen and a bcl-2-targeted siRNA-sequence on the protein 
level was applied based on cell lysates with an equal bcl-2 down-regulation of 75% 
(chapter 1). Lysates of all treatments (Oblimersen-, siRNA- and control cells) and an 
internal standard, a mixture of all samples, were labeled with Cy3 and Cy2, 
respectively (experimental setup see Materials and Methods). Protein mixtures 
labeled with these fluorescence dyes can be separated on the same 2-DE gel, 
resulting in a reliable quantitative method to monitor subtle changes in protein 
abundances with high statistical confidence since most technical variation is 
eliminated [Friedman, 2007]. Each cell treatment was performed in triplicates. 
Although the transfection reagent lipofectamine 2000 is described as cytotoxic in 
higher concentrations, 607B cells did not show increased apoptosis or Bcl-2 down-
regulation after treatment with the transfection reagent alone (chapter 3). In addition, 
no significant change in the proteomic pattern compared to untreated cells could be 
detected upon treatment with unloaded lipofectamine 2000. Consequently, 
liopfectamine only treated cells were used as control group for 2D-DIGE experiments 
comparing antisense and siRNA oligonucleotides.  
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Figure 20. Original DIGE gel images of differentially treated 607B melanoma cell lysates. 
 
Image analysis was performed with the software DeCyder [GE Healthcare, version 
6.5]. Obtained protein statistics are summarized in table 11 and 12. According to gel 
and spot quality criteria for differentially expressed proteins were chosen as follows: 
average ratio ±1.5, Student’s t-test (p ≤0.05), 1-way ANOVA (p ≥0 and ≤0.05), 
appearance in at least 16 out of 18 spot maps and match quality <6. Relevant 78 
(Oblimersen) and 8 (siRNA) spots, respectively, were subjected to a careful manual 
control,  
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Average ratio no T-Test AND no T-Test BUT ANOVA AND T-Test
no ANOVA ANOVA (p = 0 AND = 0.05) (p<0.5) (p<0.2) (p<0.1) (p<0.05)
± 1.1 1351 237 199 191 175 130
± 1.2 1168 229 194 188 174 129
± 1.3 995 214 184 180 167 126
± 1.4 836 193 165 161 151 115
± 1.5 674 156 131 128 119 78
± 1.6 571 128 105 102 95 78
± 1.7 471 98 76 73 68 53
± 1.8 405 79 61 59 55 42
± 1.9 348 61 47 45 42 31
± 2.0 301 50 36 35 32 24
± 2.5 181 24 15 15 15 9
± 3.0 144 17 10 10 10 7
± 3.5 109 11 4 4 4 3
± 4.0 84 7 2 2 2
± 4.5 67 4 1 1 1
2
1  
Table 11. Protein statistics of Oblimersen-treatment; number of spots passing different 
protein filters are listed. 78 spots met the criteria for being considered as differentially 
expressed (1.5-fold change and p<0.05) before manual control. 
 
Average ratio no T-Test AND no T-Test BUT ANOVA AND T-Test
no ANOVA ANOVA (p = 0 AND = 0.05) (p<0.5) (p<0.2) (p<0.1) (p<0.05)
± 1.1 934 156 118 76 48 33
± 1.2 653 85 64 51 34 24
± 1.3 493 56 40 34 26 17
± 1.4 373 38 24 21 18 14
± 1.5 282 25 14 12 10 8
± 1.6 210 18 9 8 7 5
± 1.7 178 13 8 8 7 5
± 1.8 150 11 6 6 5 3
± 1.9 125 10 6 6 5 3
± 2.0 104 9 5 5 5 5
± 2.5 44 4 3 3 3 2
± 3.0 18 1 1 1 1 1  
Table 12. Protein statistics of siRNA-treatment; number of spots passing different protein 
filters are listed. 8 spots met the criteria for being considered as differentially expressed (1.5-
fold change and p<0.05) before manual control. 
 
In a second evaluation step all remaining spots were checked for quality (exclusion of 
speckles and unclear, small spots with high background noise) and possible medium 
origin (e.g. BSA). Despite many washing steps during cell lysis some persistent cell 
culture components could be detected on 2-DE gels. This contamination is often 
observed when cell lysates are separated by 2-DE [Miller et al., 2006]. It can be 
reduced to a minimum but in most cases it can not be completely avoided. Figure 21 
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represents high abundant components of 607B cell culture medium separated on a 2-
DE gel in a concentration about ten times higher than present in used cell lysates.  
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Figure 21. 2-DE gel of 607B cell culture medium. 10µg of total protein, silver stained. 
Identified spots are indicated with boxes. Stathmin has been identified by direct in-gel 
digestion from DIGE gels, therefore its position on the silver-stained gel in is provided with a 
question mark. 
 
High abundant spots have been identified as serum albumin spots of bovine origin 
(P02769; 71.19kDa, pI 5.88) by MS (representative spectrum see figure 22). The 
following peaks belonging to BSA have been found: 689.46, 712.51, 733.51, 789.59, 
927.62, 1138.63, 1163.77, 1283.83, 1419.80, 1439.95, 1480.45, 1537.93, 1568.64, 
1881.10, 1908.06, 2045.24, 2301.53 and 2587.65. Comparing these 17 of 23 
peptides to protein databases (see Materials and Methods) resulted in a PMF score 
of 121 and a sequence coverage of 27%. With PSD spectra of peptides at m/z 
1480.45 and 1568.64 a PSD score of 130 was achieved. Other spots (~25kDa and 
~9kDa) have been repeatedly subjected to MALDI measurements after excision from 
silver-stained gels, but no results were obtained.  
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Figure 22. Representative peptide mass fingerprint of BSA.  
 
LGEYGFQNALIVR [MH+] 1480.45 
Mass/Charge  
Figure 22 A. Mascot result graph of the MALDI-TOF-PSD mass spectrum of the precursor 
ion m/z = 1480.45 with different ion species indicated. 
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DAFLGSFLYEYSR[MH+] 1568.64
Mass/Charge  
Figure 22 B. Mascot result graph of the MALDI-TOF-PSD mass spectrum of the precursor 
ion m/z = 1568.64 with different ion species indicated. 
 
 
Furthermore bovine stathmin (Q3T0C7; 17.3kDa, pI 5.8) was identified by MALDI-
rTOF-MS (figure 23). The following stathmin peptides were detected: 782.20, 973.31, 
1139.28, 1326.39, 1388.46 and 1604.35, resulting in a score of 61 and 34% 
sequence coverage. PSD experiments of the precursor ion 1388.46 achieved a 
protein identification score of 75. Respective spectra are shown in figure 24. 
Depending on the staining method used, proteins can show a varying protein pattern 
on a 2-DE gel and protein identification by MS may be difficult in some cases, 
especially for silver-stained gels. Stathmin has been identified by direct in-gel 
digestion from DIGE gels. Unfortunately no respective spots on silver-stained gels 
were obtained. So its position on the silver-stained medium gel in figure 21 is 
provided with a question mark. But, considering the theoretical molecular weight and 
pI, stathmin can be attributed to the ~15kDa spot. 
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Figure 23. Inverted DIGE gel of 607B cell lysate indicating the position of bovine stathmin, 
which has been identified by MALDI/MS.  
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Figure 24. Representative peptide mass fingerprint of bovine stathmin. 
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Mass/Charge
ASGQAFELILSPR[MH+] 1388.46
 
Figure 24 A. Mascot result graph of the MALDI-TOF-PSD mass spectrum of the precursor 
ion m/z = 1388.46 with different ion species indicated. 
 
 
As a results of this evaluation (taking a closer look on inherent spots originating from 
the cell medium) only two significantly changed protein spots (master gel number 
1202 and 252) remained in the siRNA group, whereas 46 spots (master gel number 
17, 150, 154, 252, 255, 259, 276, 318, 342, 359, 364, 480, 486, 493, 517, 546, 584, 
588, 627, 632, 701, 731, 743, 790, 795, 806, 856, 862, 925, 972, 1029, 1032, 1054, 
1067, 1121, 1134, 1202, 1306, 1355, 1457, 1466, 1593, 1668, 1701, 1811, 1833) 
remained in the Oblimersen group.  
The three-dimensional resolution of spots was chosen as a further quality criterium. 
Figure 25 shows three-dimensional views of selected spots, which were exported 
from DeCyder.  
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Spot 17 Spot 150+154 Spot 255Spot 252 Spot 259
Spot 276 Spot 318 Spot 342+364 Spot 359 Spot 480
Spot 486 Spot 493+517 Spot 546 Spot 588Spot 584
Spot 632 Spot 627 Spot 701 Spot 731 Spot 743
 
Spot 790 Spot 862Spot 795 Spot 806
Spot 1466
Spot 856
Spot 925 Spot 972 Spot 1029 Spot 1032 Spot 1054
Spot 1067 Spot 1121 Spot 1134 Spot 1202 Spot 1306
Spot 1355 Spot 1457 Spot 1593 Spot 1688
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Spot 1701 Spot 1811 Spot 1833
 
Figure 25. Three-dimensional views of selected protein spots exported from DeCyder. Spot 
area boundaries are indicated in magenta. Spots 150 and 154, spots 342 and 364 as well as 
spots 493 and 517 have been detected as a single spot by the software during analysis. 
 
 
Spots 790, 795 and 806 were excluded from the group of differentially expressed 
proteins due to their inadequate three-dimensional structure (figure 25). These spots 
were part of badly resolved protein mixtures at alkaline pH during isoelectric focusing. 
For a proper analysis a different pI range would have been necessary.  
 
The very small spots 701 and 856, as well as spots 1593, 1701, 1811 and 1833 could 
not be identified, since repeated extraction from gels (and pooling of protein material 
from up to five gels) did not lead to successful identification by MALDI-MS.  
Remaining 37 spots have been unambiguously identified after tryptic in-gel digestion 
and subsequent mass spectrometry using peptide mass fingerprinting in combination 
with peptide sequence tag determination. Since some spots were identified as protein 
isoforms, in total 22 proteins were found to be differentially expressed after 
Oblimersen application, whereas only two protein spots meeting the same criteria 
were detected after siRNA application. Representative MALDI PMF and PSD spectra 
for all of these proteins and experimentally found m/z values are presented in 
supplement B (figure A-V). Table 13 contains a summary of relevant MS data, 
including accession number of SwissProt, pI, molecular weight, fold change after 
treatment, statistical data (Student’s t-Test and ANOVA), PMF score, sequence 
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coverage and number of matched peptides. Continuation of table 13 contains 
additional MS/MS data including PSD score and sequences of peptides used for 
MS/MS. 
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 Table 13. List of identified differentially expressed protein species after oblimersen (A) and siRNA (B) treatment. 
Table 13 A.          
Spot number Protein name Accession number pI theor. MW [kDa] Change T-Test ANOVA PMF Score* Sequ. Cov [%] Matching peptides**
Apoptosis-related            
546 CALU O43852 4.47 37.19 - 0.0022 0.0013 93 26 10 (21) 
1668 LEG-1 P09382 5.34 14.72 - 0.0029 0.00032 121 53 9 (17) 
17/150/ 154 GRP 78 P11021 5.1 72.29 - 0.018 0.0027 94 20 13 (23) 
276 HSP-60 P10809 5.7 61.06 - 0.0011 0.00012 126 34 15 (25) 
731/ 743 NPM P06748 4.64 32.73 - 0.021 0.0027 83 39 8 (12) 
1202 PRDX-1 Q06830 8.3 22.11 - 0.029 0.0011 98 29 7 (10) 
1054 PRDX-6 P30041 6.02 25.02 - 0.023 0.0051 88 39 9 (18) 
359 TCP β  P78371 6.0 57.70 - 0.01 0.002 92 36 12 (21) 
252/ 259/ 255 TCP ε P48643 5.4 60.11 -- 0.0052 0.00047 77 20 10 (16) 
Cytoskeleton            
584/ 588 ACT B P60709 5.5 41.74 --- 0.0059 0.00051 130 31 12 (18) 
1306 COF-1 P23528 8.26 18.59 - 0.032 0.005 101 61 10 (20) 
925 Tropom yosin α Q5VU72 4.76 28.89 - 0.0063 0.0012 94 29 10 (20) 
972 Tropom yosin β  P07951 4.7 32.95 - 0.015 0.014 77 36 11 (21) 
Glycolysis           
480/ 486/ 493/ 517 ENOA-1 P06733 6.99 47.17 - 0.022 0.0047 129 21 10 (17) 
1032 PGAM-1 P18669 6.75 28.80 - 0.018 0.004 152 59 13 (20) 
627/632 PGK1 P00558 8.6 45.85 - 0.016 0.0038 82 33 9 (15) 
1067 TPIS P60174 6.51 26.81 - 0.018 0.003 129 54 12 (24) 
Miscellaneous:           
1121 MD2L1 Q13257 5.02 23.66 - 0.0043 0.00034 83 35 7 (15) 
318 PDIA-3 P30101 6.10 57.04 -- 0.027 0.018 99 27 13 (25) 
342/ 364 3-PGDH O43175 6.31 57.23 -- 0.035 0.0072 145 34 14 (20) 
1457/ 1466 PPIA P62937 7.7 18.01 - 0.036 0.0075 130 51 9 (13) 
1029 RANG P43487 5.19 23.40 - 0.049 0.023 101 49 8 (14) 
           
Table 13 B.           
Spot number Protein name e Accession number pI theor. MW [kDa] Change T-Test ANOVA PMF Score* Sequ. Cov [%] Matching peptides** 
252 TCP ε P48643 5.4 60.11 + 0.0052 0.00047 77 20 10 (20) 
1202 PRDX-1 Q06830 8.3 22.11 ++ 0.029 0.0011 98 29 7 (10) 
 
* Protein scores greater than 64 are significant (p<0.05). ** Number of unmatched peaks is given in brackets. Proteins of interest are presented with theoretical pI and MW , 
calculated statistically relevant parameters and accession numbers of the protein database. Fold changes are indicated; - / + ranges from ±1.5 to ±2.0, -- / ++ from ±2.01 to 
±3.0 and --- / +++ from ±3.01 to ±4.0. (CALU, calumenin, LEG-1, galectin-1, GRP 78, 78kDa glucose-regulated protein, HSP, heat shock protein, NPM, nucleophosmin, 
PRDX, peroxiredoxin, TCP, T-complex protein 1, ACTB, actin beta, COF-1, cofilin-1, ENOA-1, enolase-1, PGAM, phosphoglycerate mutase, PGK, phosphoglycerate kinase, 
TPIS, triosephosphatisomerase, MD2L1, mitotic-spindel-assembly-checkpoint protein MAD2A, PDIA, protein disulfide-isomerase, 3-PGDH, D-3-phosphoglycerate 
dehydrogenase, PPIA, peptidyl-prolyl cis-trans isomerase A, RANG, Ran-specific GTPase-activating protein) 
Results 
Table 13 continuation. PSD and MS/MS data of identified differentially expressed protein species after oblimersen (A) and siRNA (B) treatment.  
Table 13 A.     
Spot number Protein name Accession number Precursor ion [m/z] Peptide sequences  Score*** 
Apoptosis-related      
546 CALU O43852 955.6; 1110.6; 1581.0  EQFVEFR; WIYEDVER; TFDQLTPEESKER 203 (39)  
1668 LEG-1 P09382 1076.6; 1487.5 DGGAWGTEQR; DSNNLCLHFNPR 186 (39) 
17/150/ 154 GRP 78 P11021 1568.1; 1817.0 ITPSYVAFTPEGER; IINEPTAAAIAYGLDKR 113 (38) 
276 HSP-60 P10809 1685.6; 2561.8 AAVEEGIVLGGGCALLR; LVQDVANNTNEEAGDGTTTATVLAR 294 (37) 
731/ 743 NPM P06748 1569.7; 1821.0; 2228.6 VDNDENEHQLSLR; MTDQEAIQDLWQWR; MSVQPTVSLGGFEITPPVVLR 282 (38) 
1202 PRDX-1 Q06830 1212.8; 1360.7; 1984.0 QITVNDLPVGR; GLFIIDDKGILR; TIAQDYGVLKADEGISFR 213 (38) 
1054 PRDX-6 P30041 1086.5 LPFPIIDDR 79 (39) 
359 TCP β P78371 1331.8; 1584.3 GATQQILDEAER; QVLLSAAEAAEVILR 121 (38) 
252/ 259/ 255 TCP ε P48643 1094.8; 1739.8 IADGYEQAAR; WVGGPEIELIAIATGGR 140 (38) 
Cytoskeleton      
584/ 588 ACT B P60709 977.0; 1199.4; 1791.9 AGFAGDDAPR; AVFPSIVGRPR; SYELPDGQVITIGNER 121 (36) 
1306 COF-1 P23528 1337.0; 1341.7 YALYDATYETK; LGGSAVISLEGKPL 113 (39) 
925 Tropomyosin α Q5VU72 1400.7; 1729.2 RIQLVEEELDR; IQLVEEELDRAQER 86 (40) 
972 Tropomyosin β P07951 1539.1 TIDDLEDEVYAQK 44 (38) 
Glycolysis      
480/ 486/ 493/ 517 ENOA-1 P06733 1541.7; 1908.9 VVIGMDVAASEFFR; LAMQEFMILPVGAANFR 160 (38) 
1032 PGAM-1 P18669 613.3; 2137.4 LVLIR; FSGWYDADLSPAGHEEAKR 137 (38) 
627/632 PGK1 P00558 1636.9; 1769.8 LGDVYVNDAFGTAHR; ALESPERPFLAILGGAK 150 (39) 
1067 TPIS P60174 1587.3; 2193.2 DCGATWVVLGHSER; VPADTEVVCAPPTAYIDFAR 284 (39) 
Miscellaneous      
1121 MD2L1 Q13257  -    
318 PDIA-3 P30101 1173.5; 1759.9 FVMQEEFSR; QAGPASVPLRTEEEFK 48 (39) 
342/ 364 3-PGDH O43175 987.5 DLPLLLFR 62 (41) 
1457/ 1466 PPIA P62937 1379.7 VSFELFADKVPK 27 (39) 
1029 RANG P43487 1621.7; 2740.6 FASENDLPEWKER; AWVWNTHADFADECPKPELLAIR 122 (37) 
      
Table 13 B.      
Spot number Protein name Accession number Precursor ion [m/z] Peptide sequences Score*** 
252 TCP ε P48643 1094.8; 1739.8 IADGYEQAAR; WVGGPEIELIAIATGGR 140 (38) 
1202 PRDX-1 Q06830 1212.8; 1360.7; 1984.0 QITVNDLPVGR; GLFIIDDKGILR; TIAQDYGVLKADEGISFR 213 (38) 
 
***Ion scores greater than the number given in brackets  idicate identity or extensive homology (p<0.05). (CALU, calumenin, LEG-1, galectin-1, GRP 78, glucose-regulated
protein, HSP, heat shock protein, NPM, nucleophosmin, PRDX, peroxiredoxin, TCP, T-complex protein 1, ACTB, actin beta, COF-1, cofilin-1, ENOA-1, enolase-1, PGAM, 
phosphoglycerate mutase, PGK, phosphoglycerate kinase, TPIS, triosephosphatisomerase, MD2L1, mitotic-spindel-assembly-checkpoint protein MAD2A, PDIA, protein
disulfide-isomerase, 3-PGDH, D-3-phosphoglycerate dehydrogenase, PPIA, peptidyl-prolyl cis-trans isomerase A, RANG, Ran-specific GTPase-activating protein)  
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Figure 26. DIGE image with positions of differentially expressed protein spots indicated. 
 
All proteins with significant alterations in protein expression after antisense treatment 
were found to be down-regulated. Actin and TCP ε were down-regulated more than 
two-fold, all other proteins showed a down-regulation between 1.5 and 2 (table 13). 
TCP ε and peroxiredoxin-1, both down-regulated by Oblimersen, were the only 
proteins changed by siRNA treatment. Both proteins were up-regulated, TCP ε by 
more than 1.5 fold, and peroxiredoxin two-fold [Stessl et al., 2009]. 
Many of the differentially expressed proteins can be linked to mitochondrial apoptosis 
and drug resistance, and have been found to be up-regulated in clinical cancer 
Results 
samples or cancer cell lines. Among them are calumenin, a protein involved in the 
calcium metabolism, heat-shock protein 60, the galactose binding lectin galectin-1, 
which is up-regulated in cancer cells and activates h-ras, growth-related protein 78, 
which is implicated in mitochondrial protein import and assembly, nucleophosmin, a 
transport protein for nucleus-cytoplasm trafficking, and peroxiredoxins, which are 
involved in the redox-regulation of the cell. The cytoskeleton proteins actin, cofilin-1, 
which is also an important player in cancer cell metastasis and invasion, and 
tropomyosin were also significantly down-regulated. In addition, the expression of 
several enzymes was reduced after Oblimersen treatment. Surprisingly, four 
enzymes of the glycolytic pathway, enolase-1, phosphoglycerate kinase-1, 
triosephosphate isomerase, and phosphoglycerate mutase were found to be reduced 
in their expression, possibly indicating a reduction of anaerobic glucose consumption. 
Other identified enzymes include D-3-phosphoglycerate dehydrogenase, important 
for serine biosynthesis, peptidyl-prolyl cis-trans isomerase, often found to be up-
regulated in proteomic studies of cancer, and the protein disulfide isomerase, which 
rearranges protein disulfide bonds. Finally, the mitotic spindle assembly checkpoint 
protein MAD2A and the ran-specific GTPase-activating protein were also reduced 
after Oblimersen treatment. Figure 27 shows a schematic classification of all 
identified proteins of interest with regard to their basic cellular functions [Stessl et al., 
2009]. 
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Bcl-2 down-regulation and
apoptosis induction
Genasense application
Involvement of glycolytic enzymes
(PGK, PGAM, TPIS, ENOA-1)
Involvement of chaperones
(GRP78, HSP60, TCP subunits)
Involvement of cytoskeletal proteins
(ACTB, COF-1, tropomyosins)
Involvement of redox-regulation
(peroxiredoxins 1 and 6)
Involvement of Ca2+ signaling
(calumenin)
Involvement of other enzymes
(PDIA3, PGDH-3, PPIA-3)
Involvement of transport
proteins (nucleophosmin,
RANG)
Involvement of other proteins
(MAD2A, galectin-1)
 
Figure 27. Schematic classification of differentially expressed proteins. Picture taken from 
Stessl et al., 2009. 
Discussion 
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Gene-targeted approaches have great potential for the treatment of many severe and 
debilitating diseases [Mahato et al., 2005] but for an establishment as therapeutics 
still many difficulties, such as effective drug delivery, cellular uptake or the question 
of specificity have to be solved. Antisense oligonucleotides (ASOs) and small 
interfering RNAs (siRNAs) are two powerful tools that influence gene expression at 
the post-transcriptional level. siRNAs use the RISC-associated RNAi pathway to 
mediate gene-knockdown, which can be achieved in cell culture experiments even in 
low nanomolar concentrations, whereas phosphorothioates act via a less 
characterized mechanism usually requiring higher concentrations for efficient target 
protein knockdown. Apart from the only antisense agent on the market (fomivirsen, 
Vitravene) the ASO representative with the highest clinical relevance is the 18mer 
phosphorothioate Oblimersen (Genasense, G3139, Genta [Moreira et al., 2006]), 
which is directed against the first six codons of the open-reading frame of bcl-2. The 
anti-apoptotic protein Bcl-2 is a potent regulator of programmed cell death and its 
over-expression has been associated with decreased apoptosis and increased 
resistance against chemotherapy [Reed, 1995 and 2008]. The bcl-2-targeted 
antisense molecule Oblimersen has been tested in clinical trials against various 
cancer types, both alone and in combination with other anticancer agents. The 
rationale for testing Oblimersen is based on data supporting a relevant role for Bcl-2 
in cell survival and enhanced tumor response when it is combined with 
chemotherapy. Beyond the sequence-specific Bcl-2 down-regulation, 
phosphorothioates have been reported to have unspecific effects – studies have 
shown that several effects are caused by the CpG motifs [Gekeler et al., 2006] or the 
phosphorothioate chemistry [Stein et al., 2008]. The question of specificity and the 
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elucidation of the exact mechanism of action, however, still remain major safety 
issues for the therapeutical development of antisense agents. In this thesis a 
proteomic approach was applied in order to monitor and compare qualitative and 
quantitative off-target effects of the phosphorothioate antisense oligonucleotide 
Oblimersen and a bcl-2-targeted siRNA on the protein level with the aim to contribute 
to a better understanding of the molecular network of this compound class.  
 
In accordance with published results [Herbst et al., 2004; Benimetskaya et al., 2005; 
Wacheck et al., 2001; Jansen et al., 2000] it was found that Oblimersen down-
regulates Bcl-2 (figure 6 and 7) and induces cell death in the human melanoma cell 
line 607B (figure 9 and 10). The highest level of target protein down-regulation on 
human melanoma cells (75% compared to untreated controls) was achieved with a 
concentration of 100 nM, whereas other phosphorothioate concentrations (50 nM, 
150 nM and 200 nM, respectively) resulted in lower protein down-regulation (table 6). 
The used anti-bcl-2-siRNA was more effective, since even very low concentrations, 5 
nM and 10 nM, were enough to decrease target protein levels for ~80%. With a 
concentration of 50 nM the same Bcl-2 expression inhibition was achieved (75%), 
therefore this concentration was further chosen as siRNA working concentration. The 
same level of bcl-2 knockdown caused by the anti-bcl-2-siRNA failed to increase 
apoptosis as determined by Annexin staining and caspase activity measurement 
(figure 9 and 10). It has been previously described that Oblimersen and bcl-2-
targeted siRNAs are not equivalent as apoptotic/cytostatic agents and that they 
induce disparate phenotypes in PC3 and LNCaP prostate cancer cells [Anderson et 
al., 2006]. Together with the higher number of proteins found to be differentially 
regulated after treatment with Oblimersen compared to the siRNA treated samples 
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(table 13), it is demonstrated that an additional effect other than Bcl-2 down-
regulation is involved in the phosphorothioate mechanism. Since the effects on the 
genome and proteome level are not the same and even siRNA-sequences have 
been reported to have varying off-target effects [Jackson et al., 2003] the present 
study focused on the quantitative elucidation of off-target effects of Oblimersen and 
the anti-bcl-2 siRNA on the proteome using DIGE technology. 
 
Considering the different efficiencies in this study human melanoma cells were 
treated with 100 nM Oblimersen and 50 nM siRNA lipoplexes and after 48 hours 
subjected to lysis. In vitro applications of antisense agents are usually supported by 
transfection reagents (e.g. cationic lipids such as cholesterol derivatives) [Meidan et 
al., 2006] which facilitate their delivery and uptake into the cell. In this study all 
oligonucleotides were complexed with lipofectamine 2000. Although lipofectamine 
2000 is described as cytotoxic in higher concentrations, 607B cells did not show 
increased apoptosis or bcl-2 down-regulation after treatment with the transfection 
reagent alone (figures 6, 9 and 10). In addition, no significant change in the 
proteomic pattern compared to untreated cells could be detected upon treatment with 
unloaded lipofectamine 2000. Consequently, lipofectamine 2000 only treated cells 
were used as control group for DIGE experiments comparing antisense and siRNA 
oligonucleotides effects on the proteome level.  
 
The comparison of effects of different cell treatments on the basis of two-dimensional 
gel electrophoresis deserves a careful characterization of the used cell line, an 
optimization of separation and staining conditions for the biological question, as well 
as a validation of used bioanalytical methods in order to minimize potential bias.  
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As a first step the human melanoma cell line 607B was characterized by the 
establishment of a protein reference map (figure 16), since 607B cells have not been 
characterized on the protein level yet. Table 8 summarizes all reference proteins that 
have been unambiguously identified by in-gel digestion and subsequent MALDI-
rTOF-MS. In that context also two proteins of bovine origin were identified, namely 
bovine serum albumin (BSA) and bovine stathmin. BSA is a major component of the 
fetal calf serum, which was added to the 607B cell culture medium and stathmin, a 
protein involved in proliferation and differentiation of immortalized cells [Tamura et 
al., 2007], was most likely introduced by cell culture medium too, even though cells 
were repeatedly washed before lysis. High abundant proteins of this medium can be 
seen in figure 21. According to Miller [Miller et al., 2006] the presence of cell culture 
additives in cell lysates is a commonly observed contamination, which can be 
reduced to a minimum but cannot be completely avoided in most cases. Since the 
DIGE approach was followed by unambiguous identification of proteins by mass 
spectrometry, bovine proteins could be easily distinguished from human ones.  
 
For the two-dimensional separation of 607B lysates non linear IPG strips ranging 
from pI 3-11 and an acrylamide concentration of 12.5% were chosen. Under these 
prerequisites a high resolution could be achieved and the highest number of protein 
spots (averagely 2500-3000) could be monitored on one gel. Although the highest 
number of spots could be detected with silver staining according to Blum [Blum et al., 
1987], DIGE technology was chosen for the quantitative evaluation. It is a pre-
labeling technique with CyDyes™, which offers the high linear and dynamic range of 
fluorescent dyes, a low limit of detection and the possibility to introduce an internal 
standard providing reliable quantitative data. The disadvantage of this method is the 
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need for a post-staining with silver nitrate or fluorescent dyes, since CyDyes™, once 
linked to sample proteins, introduce a small shift in pI and molecular weight of 
proteins [Alban et al., 2003]. For subsequent MS analysis it is necessary to extract as 
much protein material as possible from 2-DE gels, therefore a post-staining is 
inevitable. Although all used methods have resulted in similar a protein pattern with 
high abundant spots present in all gels (figures 11-14), spot assignment among 
differently stained gels has been a critical issue. Physico-chemical properties of 
proteins and staining chemistry give variations which have to be taken into 
consideration as a prominent source for incorrect protein spot assignment.  
 
Beside experimental sources of variance (such as insufficient IPG strip rehydration 
prior to IEF, incomplete protein transfer from the first (IEF) to the second dimension 
(SDS-PAGE) or inhomogeneity in staining procedures [repeatedly addressed by 
Barry et al., 2003; Schlags et al., 2005; Schröder et al., 2008]), which can be widely 
avoided by the use of DIGE technology, a trained operator and respective 
equipment, variance caused by computer-assisted post-experimental processes is 
rarely considered and only a limited number of publications deal with the influence of 
the image analysis process on obtained 2-DE data [Wheelock et al., 2005 and 2006; 
Clark et al., 2008; Karp et al., 2008]. A lot of different software packages in the field 
of 2-DE image analysis are commercially available (for a detailed review see 
Marengo et al., 2005 or Berth et al., 2007). Along with high-quality technical devices 
and improved visualization methods for 2-DE gels, these packages become 
increasingly sophisticated with regard to spot detection algorithms, spot 
normalization, quantification and performance of analysis. Due to a lack of publicly 
available information regarding the algorithms used, the information about their 
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performance is limited to practical evaluation [Wheelock et al., 2006]. During the 
validation of bioanalytical methods for this thesis the question arose whether an 
analysis with the update version (8.0) of the software PD-Quest (Bio-Rad), which was 
introduced in the laboratory, would lead to different 2-DE data than an analysis with 
the original version (6.1) or with the software package Delta 2D (Decodon), 
respectively, making data comparison with older data critical or even impossible. A 
gel set of six gels was independently analyzed with the three mentioned software 
packages keeping important parameters constant (figure 17) and gained fold 
changes of selected spots were exported and compared to each other (table 10 and 
figure 19). Fold changes were represented as factors, whereupon a factor of 2 
corresponded to 100% variation in the spot volume. A spot with a factor of 2 was 
considered as differentially expressed protein. Under these prerequisites only one 
out of ten spots (VII) was detected as significantly changed with all three software 
packages, two additional spots (VIII and IX) met the criteria with both PD-Quest 
versions, but not with Delta 2D. All other spots were only detected as differentially 
expressed by one of the three software packages. Despite the inclusion of the same 
gel set and constant parameters, obtained 2-DE data differed significantly from each 
other when analysed with different software packages. During image analysis 
quantitative variation can be introduced by a lot of parameters, such as image 
acquisition, background subtraction, smoothing filters/algorithms or normalization 
methods [Wheelock et al., 2006]. The latter have to be applied in order to 
compensate for small deviations introduced by experimental procedures to improve 
software performance [Stessl et al., 2009]. For silver stained gels the total gel density 
(the raw quantity of each spot in a member gel is divided by the total intensity value 
of all the pixels in the image) is used for normalization to compensate for inconsistent 
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gel backgrounds [Zahn et al., 2003]. In the analysis with PDQ version 6.1 this method 
was considered as the most suitable one, whereas in version 8.0 the newly 
introduced local regression model was used, since it is recommended as a more 
sophisticated method. According to the manufacturer it is based upon a loess 
regression [Cleveland et al., 1988; Hua et al., 2008] and less susceptible to outliers 
than a simple linear regression [Stessl et al., 2009]. Since other mentioned 
parameters were kept constant, the study underlines the effect of the normalization 
process on obtained data. In the analysis with Delta 2D spots were normalized on the 
total quantity of spots per gel. Available information about the different algorithms 
underlying the software packages and versions is limited. Nevertheless, they highly 
influence parameters on spot quantitation [Stessl et al., 2009]. 
The software comparison of the three packages did not lead to a general judgement 
about the packages in terms of being “best in all cases”. The decision which software 
to use depends on several factors, including number of replicates, biological 
questions or applied staining methods. The study, however, clearly shows that 
quantitative data obtained with different software packages – even with different 
versions of the same software – differ significantly and are not directly comparable. 
One aim of the study was to draw the attention of the user to the fact that image-
analysis parameters chosen by the operator, the normalization processes as well as 
software algorithms can have a strong influence on the quantitative outcome.  
 
Taking these critical points of potential bias into consideration the off-target effect 
study comparing Oblimersen and a bcl-2 targeted siRNA on the basis of equal target 
protein down-regulation of 75% was performed using DIGE technology. 22 proteins 
were found to be differentially expressed after Oblimersen treatment, whereas only 2 
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proteins were significantly changed after siRNA application on human melanoma 
cells (table 13, figure 26 and 27). Beta-actin, cofilin-1, glucose-regulated protein 78, 
HSP60, nucleophosmin, phosphoglycerate mutase, protein disulfide isomerase, T-
complex proteins, and tropomyosins were also found to be differentially regulated in 
a comprehensive proteomic profiling of apoptotic cells [Thiede et al., 2004], indicating 
their significance for apoptosis. Some of these proteins (peroxiredoxins, enolase-1, 
triose phsophate isomerase, actin, TCP-1, and peptidyl-prolyl cis-trans isomerase) 
belong to a group of proteins described in a meta-analysis as repeatedly altered 
throughout many 2-DE experiments regardless of tissue or treatment [Perkins et al., 
1999]. While this may be a consequence of a technical bias, it seems more likely that 
the expression of these proteins easily fluctuates in response to a particular 
treatment or a changing environment. In any case, the significance of a differentially 
regulated protein of this “hit list” should not be over-interpreted. The reduction of the 
expression of some of the proteins, namely peptidyl-prolyl cis trans isomerse, beta-
actin, RANG, proteins involved in calcium metabolism and some cytoskeletal 
proteins, are in good agreement to a gene profiling study [Anderson et al., 2006] 
which detected several differentially regulated mRNAs to be involved in the 
phosphorothioate action mechanism [Stessl et al., 2009]. 
 
Peroxiredoxins are a family of multifunctional proteins that are involved in the cellular 
protection against oxidative stress, modulation of intracellular signaling, and 
regulation of cell proliferation [Immenschuh et al., 2005]. The context among 
peroxiredoxins, oxidative stress and apoptosis has been described [Chu et al., 2003] 
and it has been stated that high levels of peroxiredoxins inhibit apoptosis and induce 
cell proliferation. The down-regulation of peroxiredoxin-1 after Oblimersen application 
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and its converse up-regulation after siRNA-treatment are in very good accordance to 
these findings [Stessl et al., 2009]. 
Calcium ions play an important role in the complex interplay that allows signals to be 
decoded into activation of cell death [Giorgi et al., 2008]. The cytosolic Ca2+-
concentration is tightly controlled by interactions among transporters, pumps, ion 
channels and binding proteins. Calumenin (crocalbin) belongs to a family of calcium-
binding proteins, participates in Ca2+-regulated activities [Honore et al., 2000] and is 
found to be modulated in studies of apoptosis [Thiede et al., 2004] or drug resistance 
[Castagna et al., 2004; Smaili et al., 2000; Stessl et al., 2009]. 
Galectin-1 and nucleophosmin were also described to be involved in apoptosis 
regulation. A knockdown of galectin-1 sensitizes mouse melanoma cells to 
temozolomide [Mathieu et al., 2007] and furthermore it was found that it induces 
growth inhibition and apoptosis in the prostate cancer cell line LNCaP [Ellerhorst et 
al., 1999]. The multifunctional and nearly ubiquitous phosphoprotein nucleophosmin 
is dysregulated in many human malignancies leading to apoptotic resistance and 
inhibition of differentiation [Qi et al., 2008]. A specific knockdown of NPM by RNAi 
was described to attenuate apoptosis [Kerr et al., 2007; Stessl et al., 2009]. 
The cytoskeleton proteins actin and cofilin-1 are important in metastatic cancer cells 
for cell migration, metastasis and invasion, and the activity of cofilin-1 is mainly 
expression-regulated [Wang et al., 2007]. Cofilin-1 is over-expressed in many highly 
invasive cancer cell lines and in clinical tumor samples. Considering the depletion of 
other cancer markers mentioned above, the reduction of these cytoskeleton proteins 
further supports the total apoptosis-inducing and growth inhibiting effect of 
Oblimersen [Stessl et al., 2009]. 
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Besides the proteins with a connection to apoptosis or drug resistance, several 
enzymes of the glycolytic pathway were found to be down-regulated after Oblimersen 
treatment. Enolase-1 plays important additional roles in various processes. It was 
reported to be a hypoxic stress protein as well as a heat shock protein and to be 
involved in cellular energy metabolism and proliferation. Several studies have 
identified enolase-1 as an alternatively translated 37kDa tumor suppressor c-myc 
promotor binding protein (MBP-1) and ectopic MBP-1 expression was described to 
induce cell death and growth suppression [Kim et al., 2005; Subramanian et al., 
2000; Kondoh et al., 2007]. Enolase-1 is frequently found as differentially up- or 
down-regulated in 2D gel electrophoresis based proteomics experiments, underlining 
its abundance and fragility [Petrak et al., 2008]. Phosphoglycerate mutase was found 
to be up-regulated in cancer cell lines or clinical tumour samples [Turhani et al., 
2006]. The reduction in the expression of these glycolytic enzymes suggests that the 
energy metabolism of the melanoma cells changes upon Oblimersen influence 
[Stessl et al., 2009]. Most of the pyruvic acid in healthy animal and human tissues is 
obtained by normal glycolysis, id est the convertion of glucose to pyruvate. The 
pyruvate enters the mitochondria where it is oxidized to carbon dioxide (CO2) and 
water [Harris, 2006] under the formation of adenosine-5’-triphosphate (ATP) via the 
so-called “ATP synthasome” [Chen et al., 2004]. In the early part of the 20th century 
the German biochemist Otto Warburg showed that cancerous tumors develop a 
modified sugar (glucose) metabolism whereby a significant portion of the blood sugar 
consumed by the tumor is converted one step beyond pyruvate, id est to lactic acid, 
even in the presence of sufficient oxygen [Warburg et al., 1930]. That means that 
even if tumor mitochondria have sufficient oxygen to metabolize all the pyruvate 
formed from the blood glucose to carbon dioxide and water, the tumor assumes a 
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significant role in energy (ATP) production via the conversion of glucose to lactic acid 
[Pedersen, 2007]. The benefits of the Warburg effect to cancer lie (a) in an additional 
source for carbon precursors needed for the usually rapid growth of tumor cells, (b) in 
an increased protection of the tumor against the immune system caused by the low 
pH of produced lactic acid, and (c) in a kind of precaution assuring longer tumor 
survival for limited oxygen situations. The genes coding for the enzymes catalyzing 
the high glycolytic rates of tumor cells are activated under hypoxic or anoxic 
conditions [Pedersen, 2007]. Summarizing, the “Warburg effect” refers to increased 
utilization of the glycolytic pathway for energy (ATP) production (and likely other 
needs) even though sufficient oxygen is present to support mitochondrial functions of 
cancerous tumors [Pedersen, 2007]. The findings presented in this thesis may 
indicate that the Warburg effect is partially reversed after treatment with the 
phosphorothioate antisense oligonucleotide [Stessl et al., 2009]. 
As pivotal proteins involved in the Warburg effect of cancer cells hexokinase-2 and 
its receptor on the outer mitochondrial membrane, the voltage dependent anion 
channel protein (VDAC), have been identified [Bustamante et al., 1977 and 1981]. 
Hexokinase-2 bound to VDAC has preferred access to ATP synthesized in the inner 
membrane and thus facilitates the increased glycolysis of cancer cells. Furthermore 
hexokinase-2 has been reported to play a very important role in cell growth and/or 
apoptosis suppression, since its mitochondrial binding inhibits Bax-induced 
cytochrome c release and apoptosis [Pastorino et al., 2008]. VDAC has been 
described to be essential in the apoptosis-triggering change of the mitochondrial 
outer membrane permeabilization and subsequent release of cytochrome c into the 
cytoplasm [Campbell et al., 2008; Thinnes, 2009]. It is discussed as a potential 
cellular target of anti-cancer agents [Simamura et al., 2008] and has been identified 
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as a potential cellular target of phosphorothioates. The effect of Oblimersen and 
other phosphorothioates was described to be different from a general polyanion 
effect and phosphodiesters failed to increase the mitochondrial membrane 
permeability. The concentrations that effectively cause a VDAC block on isolated 
mitochondria are in the micromolar range. Upon applying a lipofectamine-
oligonucleotide mixture of 100 nM Oblimersen, the intracellular concentration was 
estimated to be up to 2 to 3 µM [Lai et al., 2006]. Furthermore VDAC was found to be 
the binding partner for hexokinase-2 and therefore it represents a key player in the 
Warburg effect. Binding to VDAC increases hexokinase-2’s affinity for ATP, providing 
it with preferred access to ATP, effectively jump starting the glycolytic pathway 
[Stessl et al., 2009].  
The over-expression of VDAC in cancer cells and its role in the activation of the 
mitochondrial apoptosis pathway and enhanced glycolysis support its potential as a 
cancer drug target [Shoshan-Barmatz et al., 2008]. Phosphorothioates have been 
shown to cause a potent specific VDAC block followed by the induction of apoptosis 
[Stein et al., 2008]. The blockage of the mitochondrial anion channel does not only 
explain the differential regulations of proteins linked to apoptosis, but also the down-
regulation of enzymes involved in the glycolytic pathway. Presented reduction in 
glycolysis on the protein level after treatment with a phosphorothioate antisense 
oligonucleotide is shown for the first time. These findings, although undesired for a 
specific gene silencing agent, might represent an interesting new therapeutic field for 
non-targeted phosphorothioate oligonucleotides or other compounds selectively 
inhibiting the VDAC. While the VDAC block is not dependent on oligonucleotide 
sequence [Stein et al., 2008], the apoptotic effect of Oblimersen is higher than that of 
an untargeted control phosphorothioate, indicating that the bcl-2 down-regulation 
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possibly along with other, yet unknown molecular targets are also contributing to its 
effect [Stessl et al., 2009].  
Control phosphorothioate oligonucleotides targeted at different proteins, not involved 
in apoptosis, (including an untargeted and an ICAM-1 targeting phosphorothioate, a 
second generation antisense oligonucleotide (2’-O-methyl gapmer), as well as an 
unmodified and a phosphorothioate backbone modified siRNA sequence) showed 
similar results compared to Oblimersen [Winkler et al., 2010]. Most proteins, namely 
glucose-related protein 78 (GRP78), galectin-1 (GAL-1), calumenin (CALU), protein-
disulfide isomerase (PDIA-3), heat-shock protein 60 (HSP60), nucleophosmin (NPM), 
cofilin-1 (COF-1), tropomyosin β, T-complex protein 1 subunit beta (TCP β), as well 
as the glycolytic enzymes triosephosphate isomerase (TPIS), glycerate aldehyde 
dehydrogenase (GAPDH), phosphoglycerate mutase (PGAM) and D-3-
phosphoglycerate dehydrogenase (PHGDH) were significantly depleted after 
treatment with control phosphorothioates or similarly modified double stranded 
siRNA. Therefore the discussed partial reversal of the Warburg effect observed after 
Oblimersen treatment seems not to be exclusively caused by bcl-2 targeted gene 
silencing and hence resulting apoptosis induction. Only Oblimersen and the random 
control antisense agent, but not an siRNA or a second generation antisense 
oligonucleotide resulted in reduced L-lactate production when normalized to glucose 
consumption. These results further indicate that the effect on glycolysis is not 
Oblimersen specific, but rather a characteristic of the phosphorothioate backbone 
modification [Winkler et al., 2010].  
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Figure 28. Visualized associations of proteins down-regulated by phosphorothioate 
treatment computed by the STRING database [Jensen et al., 2009]. These associations, 
reflecting experimental interactions, co-occurrences or co-expression of genes, as well as 
co-mentioning in Medline abstracts, show the network of the changed proteins with the 
glycolytic machinery as the central complex [Winkler et al., 2010]. LGALS1, galectin-1, 
GAPDH, glyceraldehyde-3-phosphate dehydrogenase, PDIA3, protein disulfideisomerase A3 
(58kDa glucose regulated protein), HSPA5 78 kDa glucose-regulated protein, BCL2, 
apoptosis regulator bcl-2, HSPD1, 60 kDa heat shock protein, CALU, calumenin, PHGDH, D-
3-phosphoglycerate dehydrogenase, PGAM1, phosphoglycerate mutase 1, TPM2 
tropomyosin beta chain, TPI1, triosephosphate isomerase, CFL1, cofilin-1. 
 
 
Of course, the in vivo significance of these results found in vitro remains to be 
proven. In clinical trials, Oblimersen is applied without cationic lipids. Consequently, 
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the intracellular concentrations in the organism are unknown, and may be much 
lower than those achieved in cultured cells. These data, however, demonstrate the 
possibility of clinically relevant off-target effects in oligonucleotide drug candidates 
and the need for careful pharmacologic and pharmacokinetic analysis at the 
preclinical stage of antisense or siRNA oligonucleotides. 
 
 
Conclusion  
The present study represents the first attempt to compare two different therapeutic 
gene silencing strategies with the same effect on the target in terms of their off-target 
effects on the protein level. A siRNA mediated target protein knockdown is much 
more specific and reveals hardly any off-target effects. The phosphorothioate 
antisense oligonucleotide, on the other hand, clearly shows significant unspecific 
effects on the cellular proteome, resulting in differential regulation of 22 proteins 
other than the targeted one. Identified proteins play a role in the mitochondrial 
apoptotic network, endoplasmatic reticulum stress and glycolysis. Many show an 
increased expression in cancer cell lines and clinical cancer samples, indicating that 
Oblimersen has an apoptosis inducing and resistance reversing effect. This study 
supports the theory that the Bcl-2 reduction is not the only essential molecular effect 
of Oblimersen, but that an unspecific apoptosis-induction, possibly caused by a 
phosphorothioate mediated VDAC block, also plays a key role. Furthermore the first 
evidence of a phosphorothioate oligonucleotide-mediated reduction of the expression 
of glycolytic enzymes is presented. On the one hand the findings may point to a 
potential new interesting therapeutic field for phosphorothioate oligonucleotides in 
cancer, taking advantage of their unspecific rather than their specific effects or 
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applying metabolic network based strategies. On the other hand the results underline 
the importance of the critical use of phosphorothioates in the clinic until their 
unspecific effects are fully understood.  
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          Martina Stessl  
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Supplement A 
Matrix-assisted laser desorption/ionization (MALDI)  
Today, mass spectrometry (MS) is the most useful analytical technique for protein 
and proteome analysis, as it provides a relatively robust platform for the 
determination of molecular masses and the characterization of biological molecules 
[Hjerno et al., 2007]. Depending on the desired information and the complexity of the 
samples, different strategies have evolved. For proteomics analysis and the analysis 
of large protein complexes, MS must be combined with protein or peptide separation 
techniques, which are typically one- or two-dimensional gel electrophoresis or liquid 
chromatography approaches. The individual proteins/peptides are then identified by 
searching of the obtained MS-data (m/z values) against in-silico-digested proteins 
from databases, known or predicted sequences. Correlations between the 
experimental and theoretical data are used for a statistical scoring of the probability 
for a certain protein identification [Hjerno et al., 2007]. Today, the two main 
techniques used to generate peptide and protein ions for MS analysis are matrix-
assisted laser desorption/ionization (MALDI) and electrospray ionization (ESI), which 
allow the sensitive detection of large, non-volatile and labile molecules, particularly 
proteins [Marchetti et al., 2008]. Unlike ESI, in which analyte ions are produced 
continuously, ions in MALDI are produced by pulsed-laser irradiation of the sample. 
The technique was first described in 1985 [Karas et al., 1985] and has evolved to an 
indispensable tool in life sciences and polymer analysis [Hillenkamp et al., 2007]. The 
sample is co-crystallized with a solid matrix that can absorb the wavelength of 
emitted light by the laser. In a typical UV-MALDI sample preparation small volumes of 
an analyte solution (about 10-6M) and a near saturated (ca. 0.1M) matrix solution are 
mixed, the solvent is evaporated and the matrix crystallizes to form a homogenous 
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bed of small crystals the size of which ranges from a few to a few hundred 
micrometers, depending on the matrix and preparation technique [Hillenkamp et al., 
2007]. The mixture of sample and matrix on a probe is inserted into the vacuum 
system of the MALDI instrument and after irradiation the gas-phase ions that are 
formed are directed towards the analyser [Glish et al., 2003]. 
MALDI technique has several favourable attributes, such as very high levels of 
sensitivity, often providing data from sub-femtomole (<1x10-15 moles) amounts of 
sample loading. In addition, the formation of usually singly-protonated analytes and 
the relatively high tolerance to salts and buffers facilitate further analyses [Glish et 
al., 2003]. On the one side the fact that most MALDI lasers are of pulsed nature is 
reported to be an advantage, since ions are formed in discrete events and very little 
sample is wasted, if mass analysis is coupled with ion fragmentation. On the other 
hand the pulsed nature of this technique does not allow the coupling of all available 
mass analysers. Furthermore the presence of matrix, which facilitates ionization, 
causes a large degree of chemical noise – especially at m/z ratios below 500 Da. As 
a result, low molecular weight proteins are difficult to analyse with MALDI [Glish et 
al., 2003].  
 
Matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) 
The most commonly used mass analyser in MALDI is the time-of-flight (TOF) mass 
spectrometer, which separates ions according to their velocity. Using MALDI-TOF 
m/z ratios of up to several hundred thousand can be analysed. Theoretically all ions 
are formed at the same time and space, are then accelerated (fixed potential of 1-20 
kV) towards a TOF drift tube and finally reach the detector, whereupon lower m/z 
ions achieve higher velocities and consequently arrive earlier at the detector. Thus, 
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by measuring the time it takes to reach the detector after ion formation, m/z ratios of 
the ions can be determined [Glish et al., 2003]. Better mass resolution, that is the 
ability to resolve two adjacent peaks going along with better precision (in contrast to 
mass accuracy, which provides information how close the measured mass is to the 
theoretical/true mass given in decimal points), can be gained with reflectron TOF 
instruments. In a reflectron TOF, after travelling through the first flight tube, the ions 
enter an electrostatic mirror (reflectron) which turns the ions around and directs them 
towards a second flight distance to the detector. The function of the reflectron is to 
compensate for small differences in ion velocities with the same m/z ratio, leading to 
a better resolution [Glish et al., 2003].  
 
Matrix-assisted laser desorption/ionization reflectron time-of-flight mass 
spectrometry (MALDI-rTOF-MS) 
Tandem mass spectrometry (often termed as MS/MS) involves two stages of MS. In 
the first stage ions of desired m/z (mass-to charge) ratios are isolated from the bulk 
of ions emanating from the ion source. These so-called parent ions or precursor ions 
are then induced to undergo a collision induced dissociation that changes (m) and/or 
(z). These ion products are then analysed in the second stage of the experiment, 
providing more detailed information about the ion structure [Glish et al., 2003; 
O’Connor et al., 2007]. Because of the high energy transfer during ionization the 
MALDI process generally produces metastable ions, allowing a “pseudo-MS/MS” 
technique. Selected parent ions decay either already in the ionization source, “in-
source” decay, or while passing the flight tube, “post-source” decay (PSD), and the 
fragment ions are then refocused in the reflectron. These fragment ions can be used 
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for structural characterization, provided that the sample is homogenous [O’Connor et 
al., 2007].  
 
 
Figure I. Nomenclature for peptide sequencing according to Roepstorff and Fohlman (picture 
taken from O’Connor et al., 2007). Cleavage at the amide bond is most frequently observed 
in MALDI MS/MS resulting in y- and b-ions. If the charge is retained on the C-terminal 
fragment, ions are called yn-ions. If the charge remains on the N-terminal part, ions are called 
bn-ions, where n is the number of residues in the fragment.  
 
 
For peptides, metastable decay predominantly leads to b-and y-fragments (following 
the Roepstorff nomenclature, figure 1 [Roepstorff et al., 1984]). Larger ions, and 
proteins in particular, typically lose small neutrals such as water or ammonia, which 
are not useful for structure elucidation. The yield of fragments from metastable decay 
can be increased either by choosing a “hot” matrix, such as alpha-cyano-4-cinnamic 
acid, or by prompt ion extraction in TOF mass spectrometers. Often, the yield of 
structurally relevant fragments from metastable decay is not sufficient. In this case 
the ion energy must be increased by external heating. The most common method for 
this collisional activation of the molecules is the use of inert gas in collision cell, 
which is termed collision-induced dissociation (CID). The mean collisional energy of 
individual collisions can be either only a few eV/charge (low-energy CID) or >100eV 
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(high-energy CID). The latter generates additional types of fragments that carry 
specific structrual information such as the side-chain structure in peptides (d-, w- and 
z-ions; figure 1 and 2, respectively).  
 
Figure II. Additional ion types generated by high-energy CID (picture taken from Johnson, 
1988) at the beta carbon following the loss of the gamma carbon by side chain cleavage. R' 
is the substituent, if any. Isoleucine and threonine are doubly substituted at the beta carbon, 
so that side chain loss can give rise to two different ion structures. These pairs are 
designated d and d' or w and w'. 
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Mass spectra of reference proteins 
Activator of 90kDa heat shock protein ATPase homolog 1 (AHA-1) 
The following monoisotopic m/z values were experimentally obtained: 674.40, 
816.42, 831.45, 899.47, 906.52, 919.50, 955.59, 997.54, 1088.57, 1484.71, 1713.72 
and 2717.90.  
% Int.
100
50
0
Mass/Charge 
[m/z]
1500 20001000
Figure A. Representative peptide mass fingerprint of AHA-1.  
 
ETFLTSPEELYR[MH+] 1484.64
Mass/Charge  
Figure A.a. Mascot result graph of the MALDI-TOF-PSD mass spectrum of the precursor ion 
m/z = 1484.6 with different ion species indicated. 
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ADATNVNNWHWTER[MH+] 1714.7
Mass/Charge  
Figure A.b. Mascot result graph of the MALDI-TOF-PSD mass spectrum of the precursor ion 
m/z = 1714.7 with different ion species indicated. 
 
T-complex protein 1 subunit zeta (TCP-1 zeta) 
The following monoisotopic m/z values were experimentally obtained: 572.56, 
615.56, 750.64, 757.60, 800.61, 906.56, 916.61, 937.62, 1021.72, 1076.80, 1078.76, 
1191.63, 1255.91, 1498.94, 1762.06, 2202.20 and 2544.47.  
% Int.
100
50
0
Mass/Charge 
[m/z]
1500 20001000
Figure B. Representative peptide mass fingerprint of TCP-1 zeta.  
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EGIVALR[MH+] 758.0
Mass/Charge  
Figure B.a. Mascot result graph of the MALDI-TOF-PSD mass spectrum of the precursor ion 
m/z = 758.0 with different ion species indicated. 
 
 
GLVLDHGAR[MH+] 938.5
Mass/Charge  
Figure B.b. Mascot result graph of the MALDI-TOF-PSD mass spectrum of the precursor ion 
m/z = 938.5 with different ion species indicated. 
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QADLYISEGLHPR[MH+] 1499.5
Mass/Charge  
Figure B.c. Mascot result graph of the MALDI-TOF-PSD mass spectrum of the precursor ion 
m/z = 1499.5 with different ion species indicated. 
 
Elongation factor 2 (EF-2) 
The following monoisotopic m/z values were experimentally obtained: 687.54, 
752.69, 754.00, 758.68, 760.60, 821.66, 837.61, 890.73, 922.68, 969.78, 1013.73, 
1091.81, 1378.97, 1743.07, 1800.15 and 2220.24. 
% Int.
100
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0
Mass/Charge 
[m/z]
1500 20001000
Figure C. Representative peptide mass fingerprint of EF-2.  
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GGGQIIPTAR[MH+] 970.0
Mass/Charge  
Figure C.a. Mascot result graph of the MALDI-TOF-PSD mass spectrum of the precursor ion 
m/z = 970.0 with different ion species indicated. 
 
 
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
The following monoisotopic m/z values were experimentally obtained: 685.51, 
688.45, 795.52, 811.52, 909.61, 1411.88, 1530.83 and 1763.76. 
% Int.
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0
Mass/Charge 
[m/z]
1500 20001000
Figure D. Representative peptide mass fingerprint of GAPDH.  
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LISWYDNEFGYSNR[MH+] 1764.3
Mass/Charge  
Figure D.a. Mascot result graph of the MALDI-TOF-PSD mass spectrum of the precursor ion 
m/z = 1764.3 with different ion species indicated. 
 
H+ATPase lysosomal (V-type proton ATPase subunit B)  
The following monoisotopic m/z values were experimentally obtained: 524.29, 
599.46, 632.22, 743.62, 873.62, 877.59, 1104.77, 1308.79, 1437.89, 1594.01, 
1597.06, 1758.02 and 1896.96. 
% Int.
100
50
0
Mass/Charge 
[m/z]
1500 20001000
Figure E. Representative peptide mass fingerprint of H+ATPase lysosomal.  
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NFIAQGPYENR[MH+] 1309.8
Mass/Charge  
Figure E.a. Mascot result graph of the MALDI-TOF-PSD mass spectrum of the precursor ion 
m/z = 1309.8 with different ion species indicated. 
 
 
Heat shock cognate 71kDa protein (HSP 70) 
The following monoisotopic m/z values were experimentally obtained: 614.47; 
687.49, 765.50, 774.54, 858.56, 861.54, 905.49, 930.65, 944.57, 989.61, 1017.65, 
1081.70, 1199.80, 1228.73, 1235.75, 1253.76, 1410.79, 1480.83, 1487.78, 1691.83, 
1982.10, 2774.30 and 2997.56.  
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100
50
0
Mass/Charge 
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Figure F. Representative peptide mass fingerprint of HSP-70.  
 
 
DAGTIAGLNVLR[MH+] 1200.3
Mass/Charge  
Figure F.a. Mascot result graph of the MALDI-TOF-PSD mass spectrum of the precursor ion 
m/z = 1200.3 with different ion species indicated. 
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Heat shock protein HSP 90-alpha (HSP-90) 
The following monoisotopic m/z values were experimentally obtained: 673.53, 
677.50, 681.49, 706.56, 722.56, 730.58, 815.65, 858.69, 901.77, 1168.79, 1236.84, 
1242.89, 1265.83, 1349.91, 1513.93, 1560.96 and 1590.00. 
% Int.
100
50
0
Mass/Charge 
[m/z]
15001000
 
Figure G. Representative peptide mass fingerprint of HSP-90.  
 
LSELLR[MH+] 730.8
Mass/Charge  
Figure G.a. Mascot result graph of the MALDI-TOF-PSD mass spectrum of the precursor ion 
m/z = 730.8 with different ion species indicated. 
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IDIIPNPQER[MH+] 1195.6
Mass/Charge  
Figure G.b. Mascot result graph of the MALDI-TOF-PSD mass spectrum of the precursor ion 
m/z = 1195.6 with different ion species indicated. 
 
L-lactate dehydrogenase A chain (LDH) 
The following monoisotopic m/z values were experimentally obtained: 742.58, 
913.78, 959.71, 1248.84 and 1267.96. 
% Int.
100
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0
Mass/Charge 
[m/z]15001000  
Figure H. Representative peptide mass fingerprint of LDH.  
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LNLVQR[MH+] 743.0
Mass/Charge  
Figure H.a. Mascot result graph of the MALDI-TOF-PSD mass spectrum of the precursor ion 
m/z = 743.0 with different ion species indicated. 
 
 
IVVVTAGVR[MH+] 914.5
Mass/Charge  
Figure H.b. Mascot result graph of the MALDI-TOF-PSD mass spectrum of the precursor ion 
m/z = 914.5 with different ion species indicated. 
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Stress-70 protein, mitochondrial (Mortalin) 
The following monoisotopic m/z values were experimentally obtained: 715.54, 
774.69, 862.60, 958.75, 994.27, 1242.79, 1333.18, 1361.92, 1405.66, 1446.85, 
1462.29, 1518.00, 1569.93, 1593.10, 1695.02 and 2056.10. 
% Int.
100
50
0
Mass/Charge 
[m/z]
1500 20001000
 
Figure I. Representative peptide mass fingerprint of Mortalin.  
 
AQFEGIVTDLIR[MH+] 1362.5
Mass/Charge  
Figure I.a. Mascot result graph of the MALDI-TOF-PSD mass spectrum of the precursor ion 
m/z = 1362.5 with different ion species indicated. 
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Nucleoside diphosphate kinase A (NDK-A) 
The following monoisotopic m/z values were experimentally obtained: 707.35, 
828.33, 984.46, 1051.34, 1149.44, 1344.53 and 1785.63.  
% Int.
100
50
0
Mass/Charge 
[m/z]1500 20001000  
Figure J. Representative peptide mass fingerprint of NDK-A.  
 
GDFCIQVGR[MH+] 1052.5
Mass/Charge  
Figure J.a. Mascot result graph of the MALDI-TOF-PSD mass spectrum of the precursor ion 
m/z = 1052.5 with different ion species indicated. 
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TFIAIKPDGVQR[MH+] 1345.4
Mass/Charge  
Figure J.b. Mascot result graph of the MALDI-TOF-PSD mass spectrum of the precursor ion 
m/z = 1345.4 with different ion species indicated. 
 
Protein disulfide-isomerase A6 (PDIA6) 
The following monoisotopic m/z values were experimentally obtained: 591.44, 
662.41, 676.45, 708.42, 758.50, 1015.68, 1151.72, 1386.85, 1483.84, 1527.93, 
1667.89, 2356.22 and 2581.37. 
% Int.
100
50
0
Mass/Charge 
[m/z]1500 20001000  
Figure K. Representative peptide mass fingerprint of PDIA6.  
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LAAVDATVNQVLASR[MH+] 1528.7
Mass/Charge  
Figure K.a. Mascot result graph of the MALDI-TOF-PSD mass spectrum of the precursor ion 
m/z = 1528.7 with different ion species indicated. 
 
Lamin A/C (Progerin) 
The following monoisotopic m/z values were experimentally obtained: 515.51, 
861.36, 919.58, 972.70, 1028.81, 1057.87, 1089.79, 1104.89, 1187.88, 1359.05, 
1509.91, 1606.04, 1649.99, 1753.15 and 2384.21.  
% Int.
100
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0
Mass/Charge 
[m/z]1500 20001000
Figure L. Representative peptide mass fingerprint of Progerin.  
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Proteasome subunit alpha type-3 (PSA-3) 
The following monoisotopic m/z values were experimentally obtained: 745.55, 
763.52, 1095.68, 1114.69, 1152.73, 1217.80, 1237.77, 1396.91 and 1578.97.  
% Int.
100
50
0
Mass/Charge 
[m/z]1500 20001000  
Figure M. Representative peptide mass fingerprint of PSA-3.  
 
 
SLADIAREEASNFR[MH+] 1579.3
Mass/Charge  
Figure M.a. Mascot result graph of the MALDI-TOF-PSD mass spectrum of the precursor ion 
m/z = 1579.3 with different ion species indicated. 
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Bifunctional purine biosynthesis protein PURH 
The following monoisotopic m/z values were experimentally obtained: 701.49, 
890.66, 1042.79, 1142.71, 1163.78, 1245.74, 1309.85, 1355.99, 1384.87, 1607.94, 
1623.93, 2035.21, 2163.29 and 2559.29.  
% Int.
100
50
0
Mass/Charge 
[m/z]1500 20001000  
Figure N. Representative peptide mass fingerprint of PURH. 
 
 
 
 
 
 
Stress-induced-phosphoprotein 1 (STIP-1) 
The following monoisotopic m/z values were experimentally obtained: 616.71, 
628.62, 644.62, 652.64, 672.67, 769.57, 800.82, 900.67, 915.65, 1008.88, 1065.71 
and 1464.87. 
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[m/z]1500 20001000  
Figure O. Representative peptide mass fingerprint of STIP-1.  
 
 
LDPHNHVLYSNR [MH+] 1465.8
Mass/Charge  
Figure O.a. Mascot result graph of the MALDI-TOF-PSD mass spectrum of the precursor ion 
m/z = 1465.8 with different ion species indicated. 
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Tyrosyl-tRNA synthetase, cytoplasmic (SYYC) 
The following monoisotopic m/z values were experimentally obtained: 702.54, 
706.55, 721.43, 726.59, 744.55, 752.58, 764.53, 790.56, 863.65, 973.68, 985.66, 
1011.68, 1205.76, 1235.81, 1256.77 and 1793.86. 
% Int.
100
50
0
Mass/Charge 
[m/z]1500 20001000  
Figure P. Representative peptide mass fingerprint of SYYC.  
 
EYTLDVYR  [MH+] 1059.7
Mass/Charge  
Figure P.a. Mascot result graph of the MALDI-TOF-PSD mass spectrum of the precursor ion 
m/z = 1059.7 with different ion species indicated. 
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VDAQFGGIDQR [MH+] 1206.7
Mass/Charge  
Figure P.b. Mascot result graph of the MALDI-TOF-PSD mass spectrum of the precursor ion 
m/z = 1206.7 with different ion species indicated. 
 
Tubulin beta chain  
The following monoisotopic m/z values were experimentally obtained: 1028.44, 
1039.51, 1077.42, 1130.53, 1143.56, 1229.55, 1271.63, 1301.52, 1385.54, 1615.62, 
1620.67, 1696.57, 1869.67, 1958.64, 2086.71, 2708.54, 2798.55, 2855.52, 3102.44 
and 4593.57.  
% Int.
100
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0
Mass/Charge 
[m/z]1500 20001000 2500 35003000 4000
Figure Q. Representative peptide mass fingerprint of Tubulin.  
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YLTVAAVFR [MH+] 1039.4
Mass/Charge  
Figure Q.a. Mascot result graph of the MALDI-TOF-PSD mass spectrum of the precursor ion 
m/z = 1039.4 with different ion species indicated. 
 
 
FPGQLNADLR [MH+] 1131.6
Mass/Charge  
Figure Q.b. Mascot result graph of the MALDI-TOF-PSD mass spectrum of the precursor ion 
m/z = 1131.6 with different ion species indicated. 
 
 148
Supplement 
SGPFGQIFRPDNFVFGQSGAGNNWAK [MH+] 2799.8
Mass/Charge  
Figure Q.c. Mascot result graph of the MALDI-TOF-PSD mass spectrum of the precursor ion 
m/z = 2799.8 with different ion species indicated. 
 
Ubiquitin 
The following monoisotopic m/z values were experimentally obtained: 648.60, 
717.63, 765.67, 1039.84, 1067.90, 1081.79, 1524.03 and 1788.20. 
% Int.
100
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[m/z]1500 20001000  
Figure R. Representative peptide mass fingerprint of Ubiquitin.  
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EGIPPDQQR[MH+] 1039.4
Mass/Charge  
Figure R.a. Mascot result graph of the MALDI-TOF-PSD mass spectrum of the precursor ion 
m/z = 1039.4 with different ion species indicated. 
 
 
Vimentin  
The following monoisotopic m/z values were experimentally obtained: 519.38, 
545.42, 573.41, 587.48, 605.41, 645.42, 701.46, 743.57, 872.50, 914.51, 932.56, 
970.66, 1028.55, 1068.55, 1088.58, 1093.58, 1125.63, 1270.54, 1295.64, 1311.65, 
1428.67, 1495.74, 1510.71, 1570.87, 1824.84 and 2496.99. 
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Figure S. Representative peptide mass fingerprint of Vimentin.  
 
ISLPLPNFSSLNLR[MH+] 1571.7
Mass/Charge  
Figure S.a. Mascot result graph of the MALDI-TOF-PSD mass spectrum of the precursor ion 
m/z = 1571.7 with different ion species indicated. 
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Supplement B 
Mass spectra of differentially expressed proteins 
Calumenin (CALU) 
The following monoisotopic m/z values were experimentally obtained: 954.63, 
1109.70, 1197.97, 1232.86, 1340.81, 1579.88, 1887.92, 1988.17, 2701.47, and 
3101.80. 
% Int.
100
50
0
Mass/Charge 
[m/z]1500 2000 25001000  
Figure A. Representative peptide mass fingerprint of CALU.  
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EQFVEFR[MH+] 955.6
Mass/Charge  
Figure A.a. Mascot result graph of the MALDI-TOF-PSD mass spectrum of the precursor ion 
m/z = 955.6 with different ion species indicated. 
 
 
WIYEDVER[MH+] 1110.6
Mass/Charge  
Figure A.b. Mascot result graph of the MALDI-TOF-PSD mass spectrum of the precursor ion 
m/z = 1110.6 with different ion species indicated. 
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TFDQLTPEESKER[MH+] 1581.0
Mass/Charge  
Figure A.c. Mascot result graph of the MALDI-TOF-PSD mass spectrum of the precursor ion 
m/z = 1581.0 with different ion species indicated. 
 
 
Galectin-1 (LEG-1) 
The following monoisotopic m/z values were experimentally obtained: 533.45, 
611.40, 877.68, 968.69, 1041.83, 1076.74, 1482.98, 1486.96, and 1648.03.  
% Int.
100
50
0
Mass/Charge 
[m/z]1500 20001000  
Figure B. Representative peptide mass fingerprint of galectin-1.  
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DGGAWGTEQR[MH+] 1076.6
Mass/Charge  
Figure B.a. Mascot result graph of the MALDI-TOF-PSD mass spectrum of the precursor ion 
m/z = 1076.6 with different ion species indicated. 
 
 
DSNNLCLHFNPR[MH+] 1487.5
Mass/Charge  
Figure B.b. Mascot result graph of the MALDI-TOF-PSD mass spectrum of the precursor ion 
m/z = 1487.5 with different ion species indicated. 
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78kDa glucose-regulated protein (GRP78) 
The following monoisotopic m/z values were experimentally obtained: 986.15, 
1168.56, 1307.63, 1323.58, 1460.75, 1512.70, 1566.72, 1588.82, 1815.88, 1887.94, 
1934.00, and 2164.94. 
100
50
0
Int. [%] 
Mass/Charge 
[m/z]1500 20001000  
Figure C. Representative peptide mass fingerprint of GRP78.  
 
ITPSYVAFTPEGER[MH+] 1568.1
Mass/Charge  
Figure C.a. Mascot result graph of the MALDI-TOF-PSD mass spectrum of the precursor ion 
m/z = 1568.1 with different ion species indicated. 
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IINEPTAAAIAYGLDKR [MH+] 1817.04
Mass/Charge  
Figure C.b. Mascot result graph of the MALDI-TOF-PSD mass spectrum of the precursor ion 
m/z = 1817.04 with different ion species indicated. 
 
Heat shock protein 60 (HSP60) 
The following monoisotopic m/z values were experimentally obtained: 636.26, 
833.35, 855.47, 941.55, 960.44, 1231.55, 1233.58, 1344.57, 1684.70, 1804.76, 
1922.80, 2129.50, 2295.65, 2560.45, and 2836.88. 
% Int.
100
50
0
Mass/Charge 
[m/z]1500 2000 25001000  
Figure D. Representative peptide mass fingerprint of HSP60.  
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AAVEEGIVLGGGCALLR[MH+] 1685.6
Mass/Charge  
Figure D.a. Mascot result graph of the MALDI-TOF-PSD mass spectrum of the precursor ion 
m/z = 1685.6 with different ion species indicated. 
 
LVQDVANNTNEEAGDGTTTATVLAR[MH+] 2561.8
Mass/Charge  
Figure D.b. Mascot result graph of the MALDI-TOF-PSD mass spectrum of the precursor ion 
m/z = 2561.8 with different ion species indicated. 
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Supplement 
Nucleophosmin (NPM) 
The following monoisotopic m/z values were experimentally obtained: 806.43, 
931.45, 974.61, 1568.77, 1819.90, 1835.98, 2227.24, and 2929.71.  
% Int.
100
50
0
Mass/Charge 
[m/z]1500 2000 25001000  
Figure E. Representative peptide mass fingerprint of NPM.  
 
VDNDENEHQLSLR[MH+] 1569.7
Mass/Charge  
Figure E.a. Mascot result graph of the MALDI-TOF-PSD mass spectrum of the precursor ion 
m/z = 1569.7 with different ion species indicated. 
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MTDQEAIQDLWQWR[MH+] 1821.0
Mass/Charge  
Figure E.b. Mascot result graph of the MALDI-TOF-PSD mass spectrum of the precursor ion 
m/z = 1821.0 with different ion species indicated. 
 
MSVQPTVSLGGFEITPPVVLR[MH+] 2228.6
Mass/Charge  
Figure E.c. Mascot result graph of the MALDI-TOF-PSD mass spectrum of the precursor ion 
m/z = 2228.6 with different ion species indicated. 
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Supplement 
Peroxiredoxin (PRDX-1) 
The following monoisotopic m/z values were experimentally obtained: 819.32, 
894.32, 1107.43, 1196.53, 1211.56, 1359.67, and 1982.81.  
% Int.
100
50
0
Mass/Charge 
[m/z]1500 2000
25001000
 
Figure F. Representative peptide mass fingerprint of PRDX-1.  
 
QITVNDLPVGR[MH+] 1212.8
Mass/Charge  
Figure F.a. Mascot result graph of the MALDI-TOF-PSD mass spectrum of the precursor ion 
m/z = 1212.8 with different ion species indicated. 
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GLFIIDDKGILR[MH+] 1360.7
Mass/Charge  
Figure F.b. Mascot result graph of the MALDI-TOF-PSD mass spectrum of the precursor ion 
m/z = 1360.7 with different ion species indicated. 
 
 
TIAQDYGVLKADEGISFR[MH+] 1984.0
Mass/Charge  
Figure F.c. Mascot result graph of the MALDI-TOF-PSD mass spectrum of the precursor ion 
m/z = 1984.0 with different ion species indicated. 
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Supplement 
Peroxiredoxin-6 (PRDX-6) 
The following monoisotopic m/z values were experimentally obtained: 906.40, 
1085.47, 1191.53, 1356.73, 1395.57, 1512.68, 1884.85, and 2097.84. 
% Int.
100
50
0
Mass/Charge 
[m/z]1500 2000 25001000  
Figure G. Representative peptide mass fingerprint of PRDX-6.  
 
LPFPIIDDR[MH+] 1086.5
Mass/Charge  
Figure G.a. Mascot result graph of the MALDI-TOF-PSD mass spectrum of the precursor ion 
m/z = 1086.5 with different ion species indicated. 
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T-complex protein 1 subunit beta (TCP β) 
The following monoisotopic m/z values were experimentally obtained: 745.52, 
870.67, 1130.73, 1291.89, 1330.79, 1407.04, 1481.66, 1530.96, 1549.03, 1583.09, 
1956.20, and 3209.8.  
% Int.
100
50
0
Mass/Charge 
[m/z]1500 2000
25001000
 
Figure H. Representative peptide mass fingerprint of TCP β.  
GATQQILDEAER[MH+] 1331.8
Mass/Charge  
Figure H.a. Mascot result graph of the MALDI-TOF-PSD mass spectrum of the precursor ion 
m/z = 1331.8 with different ion species indicated. 
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QVLLSAAEAAEVILR[MH+] 1584.3
Mass/Charge  
Figure H.b. Mascot result graph of the MALDI-TOF-PSD mass spectrum of the precursor ion 
m/z = 1584.3 with different ion species indicated. 
 
T-complex protein 1 subunit epsilon (TCP ε) 
The following monoisotopic m/z values were experimentally obtained: 692.53, 
819.67, 924.58, 1093.66, 1168.74, 1183.80, 1205.87, 1268.91, 1739.11, and 
1911.18. 
% Int.
100
50
0
Mass/Charge 
[m/z]1500 20001000  
Figure I. Representative peptide mass fingerprint of TCP ε.  
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IADGYEQAAR[MH+] 1094.8
Mass/Charge  
Figure I.a. Mascot result graph of the MALDI-TOF-PSD mass spectrum of the precursor ion 
m/z = 1094.8 with different ion species indicated. 
 
 
WVGGPEIELIAIATGGR[MH+] 1739.8
Mass/Charge  
Figure I.b. Mascot result graph of the MALDI-TOF-PSD mass spectrum of the precursor ion 
m/z = 1739.8 with different ion species indicated. 
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Actin, cytoplasmatic 1 (ACTB) 
The following monoisotopic m/z values were experimentally obtained: 516.36, 
631.27, 644.47, 777.51, 795.54, 976.54, 1014.71, 1132.75, 1198.92, 1516.04, 
1791.06, and 1954.22. 
% Int.
100
50
0
Mass/Charge 
[m/z]15001000  
Figure J. Representative peptide mass fingerprint of ACTB.  
 
AGFAGDDAPR[MH+] 977.0
Mass/Charge  
Figure J.a. Mascot result graph of the MALDI-TOF-PSD mass spectrum of the precursor ion 
m/z = 977.0 with different ion species indicated. 
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AVFPSIVGRPR[MH+] 1199.4
Mass/Charge  
Figure J.b. Mascot result graph of the MALDI-TOF-PSD mass spectrum of the precursor ion 
m/z = 1199.4 with different ion species indicated. 
 
SYELPDGQVITIGNER[MH+] 1791.9
Mass/Charge  
Figure J.c. Mascot result graph of the MALDI-TOF-PSD mass spectrum of the precursor ion 
m/z = 1791.9 with different ion species indicated. 
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Supplement 
Cofilin-1 (COF-1) 
The following monoisotopic m/z values were experimentally obtained: 721.44, 
753.53, 799.55, 915.58, 1034.66, 1309.78, 1337.73, 1340.96, 1790.82, and 1990.10. 
% Int.
100
50
0
Mass/Charge 
[m/z]1500 20001000  
Figure K. Representative peptide mass fingerprint of COF-1.  
 
 
YALYDATYETK[MH+] 1337.0
Mass/Charge  
Figure K.a. Mascot result graph of the MALDI-TOF-PSD mass spectrum of the precursor ion 
m/z = 1337.0 with different ion species indicated. 
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LGGSAVISLEGKPL[MH+] 1341.7
Mass/Charge  
Figure K.b. Mascot result graph of the MALDI-TOF-PSD mass spectrum of the precursor ion 
m/z = 1341.7 with different ion species indicated. 
 
Tropomyosin α 
The following monoisotopic m/z values were experimentally obtained: 894.73, 
1228.91, 1243.95, 1285.05, 1316.95, 1400.02, 1544.06, 1672.23, 1728.18, and 
1784.23. 
% Int.
100
50
0
Mass/Charge 
[m/z]1500 20001000  
Figure L. Representative peptide mass fingerprint of Tropomyosin alpha.  
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RIQLVEEELDR[MH+] 1400.7
Mass/Charge  
Figure L.a. Mascot result graph of the MALDI-TOF-PSD mass spectrum of the precursor ion 
m/z = 1400.7 with different ion species indicated. 
 
IQLVEEELDRAQER[MH+] 1729.2
Mass/Charge  
Figure L.b. Mascot result graph of the MALDI-TOF-PSD mass spectrum of the precursor ion 
m/z = 1729.2 with different ion species indicated. 
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Supplement 
Tropomyosin β 
The following monoisotopic m/z values were experimentally obtained: 1069.64, 
1091.62, 1092.70, 1106.67, 1148.70, 1164.71, 1169.74, 1233.71, 1307.70, 1537.90, 
and 1717.06. 
% Int.
100
50
0
Mass/Charge 
[m/z]1500 20001000  
Figure M. Representative peptide mass fingerprint of Tropomyosin beta.  
 
TIDDLEDEVYAQK[MH+] 1539.1
Mass/Charge  
Figure M.a. Mascot result graph of the MALDI-TOF-PSD mass spectrum of the precursor ion 
m/z = 1539.1 with different ion species indicated. 
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Alpha-enolase (ENOA-1) 
The following monoisotopic m/z values were experimentally obtained: 661.37, 
704.49, 766.45, 801.56, 806.53, 1007.6, 1540.92, 1805.10, 1908.13, and 2176.17. 
% Int.
100
50
0
Mass/Charge 
[m/z]1500 2000 25001000  
Figure N. Representative peptide mass fingerprint of ENOA-1.  
 
VVIGMDVAASEFFR[MH+] 1541.7
Mass/Charge  
Figure N.a. Mascot result graph of the MALDI-TOF-PSD mass spectrum of the precursor ion 
m/z = 1541.7 with different ion species indicated. 
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LAMQEFMILPVGAANFR[MH+] 1908.9
Mass/Charge  
Figure N.b. Mascot result graph of the MALDI-TOF-PSD mass spectrum of the precursor ion 
m/z = 1908.9 with different ion species indicated. 
 
Phosphoglycerate mutase 1 (PGAM-1) 
The following monoisotopic m/z values were experimentally obtained: 601.44, 
613.52, 757.56, 768.51, 1059.63, 1150.78, 1174.41, 1312.73, 1684.00, 1935.94, 
2136.03, 2156.21, and 2417.12. 
% Int.
100
50
0
Mass/Charge 
[m/z]1500 20001000  
Figure O. Representative peptide mass fingerprint of PGAM-1.  
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LVLIR[MH+] 613.3
Mass/Charge  
Figure O.a. Mascot result graph of the MALDI-TOF-PSD mass spectrum of the precursor ion 
m/z = 613.3 with different ion species indicated. 
 
FSGWYDADLSPAGHEEAKR[MH+] 2137.4
Mass/Charge  
Figure O.b. Mascot result graph of the MALDI-TOF-PSD mass spectrum of the precursor ion 
m/z = 2137.4 with different ion species indicated. 
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Supplement 
Phosphoglycerate kinase 1 (PGK-1) 
The following monoisotopic m/z values were experimentally obtained: 1101.56, 
1159.54, 1190.58, 1217.60, 1434.69, 1634.74, 1768.87, 2022.92, and 2104.88. 
% Int.
100
50
0 Mass/Charge 
[m/z]1500 20001000  
Figure P. Representative peptide mass fingerprint of PGK-1.  
 
LGDVYVNDAFGTAHR[MH+] 1636.9
Mass/Charge  
Figure P.a. Mascot result graph of the MALDI-TOF-PSD mass spectrum of the precursor ion 
m/z = 1636.9 with different ion species indicated. 
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ALESPERPFLAILGGAK[MH+] 1769.8
Mass/Charge  
Figure P.b. Mascot result graph of the MALDI-TOF-PSD mass spectrum of the precursor ion 
m/z = 1769.8 with different ion species indicated. 
 
Triosephosphate isomerase (TPIS) 
The following monoisotopic m/z values were experimentally obtained: 621.41, 
850.64, 954.67, 1082.79, 1137.80, 1234.86, 1326.90, 1458.98, 1466.97, 1587.05, 
1808.34, and 2192.53. 
% Int.
100
50
0
Mass/Charge 
[m/z]1500 2000 25001000  
Figure Q. Representative peptide mass fingerprint of TPIS.  
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DCGATWVVLGHSER[MH+] 1587.3
Mass/Charge  
Figure Q.a. Mascot result graph of the MALDI-TOF-PSD mass spectrum of the precursor ion 
m/z = 1587.3 with different ion species indicated. 
 
 
VPADTEVVCAPPTAYIDFAR[MH+] 2193.2
Mass/Charge  
Figure Q.b. Mascot result graph of the MALDI-TOF-PSD mass spectrum of the precursor ion 
m/z = 2193.2 with different ion species indicated. 
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Supplement 
Mitotic spindle assembly checkpoint protein MAD2A (MD2L1) 
The following monoisotopic m/z values were experimentally obtained: 799.71, 
816.76, 844.51, 1299.71, 1326.63, 2348.06, and 2688.36. 
% Int.
100
50
0
Mass/Charge 
[m/z]1500 20001000  
Figure R. Representative peptide mass fingerprint of MD2L1.  
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Protein disulfide-isomerase A3 (PDIA-3) 
The following monoisotopic m/z values were experimentally obtained: 877.52, 
995.21, 1172.40, 1188.40, 1191.48, 1359.49, 1370.58, 1515.62, 1652.61, 1664.63, 
1758.73, 2703.89, and 2938.49. 
% Int.
100
50
0
Mass/Charge 
[m/z]1500 2000 25001000  
Figure S. Representative peptide mass fingerprint of PDIA-3.  
 
FVMQEEFSR[MH+] 1173.5
Mass/Charge  
Figure S.a. Mascot result graph of the MALDI-TOF-PSD mass spectrum of the precursor ion 
m/z = 1173.5 with different ion species indicated. 
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QAGPASVPLRTEEEFK[MH+] 1759.9
Mass/Charge  
Figure S.b. Mascot result graph of the MALDI-TOF-PSD mass spectrum of the precursor ion 
m/z = 1759.9 with different ion species indicated. 
 
D-3-phosphoglycerate dehydrogenase (3-PGDH) 
The following monoisotopic m/z values were experimentally obtained: 716.42, 
718.47, 986.54, 1099.53, 1225.73, 1298.77, 1434.78, 1488.77, 1624.62, 1809.84, 
2048.06, 2274.14, 2288.36, and 2488.03. 
% Int.
100
50
0
Mass/Charge 
[m/z]1500 20001000  
Figure T. Representative peptide mass fingerprint of 3-PGDH.  
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DLPLLLFR[MH+] 987.5
Mass/Charge  
Figure T.a. Mascot result graph of the MALDI-TOF-PSD mass spectrum of the precursor ion 
m/z = 987.5 with different ion species indicated. 
 
 
Peptidyl-prolyl cis-trans isomerase A (PPIA) 
The following monoisotopic m/z values were experimentally obtained: 686.29, 
737.26, 763.22, 765.34, 1154.49, 1379.70, 1598.75, 1831.89, and 1946.01.  
% Int.
100
50
0
Mass/Charge 
[m/z]1500 2000 25001000  
Figure U. Representative peptide mass fingerprint of PPIA. 
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VSFELFADKVPK[MH+] 1379.7
Mass/Charge  
Figure U.a. Mascot result graph of the MALDI-TOF-PSD mass spectrum of the precursor ion 
m/z = 1379.7 with different ion species indicated. 
 
 
Ran-specific GTPase-activating protein (RANG) 
The following monoisotopic m/z values were experimentally obtained: 969.59, 
1034.51, 1309.74, 1335.58, 1381.59, 1620.68, 2739.57, and 3933.83. 
% Int.
100
50
0
Mass/Charge 
[m/z]1500 2000 25001000 3000 3500  
Figure V. Representative peptide mass fingerprint of RANG.  
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FASENDLPEWKER[MH+] 1621.7
Mass/Charge  
Figure V.a. Mascot result graph of the MALDI-TOF-PSD mass spectrum of the precursor ion 
m/z = 1621.7 with different ion species indicated. 
 
AWVWNTHADFADECPKPELLAIR[MH+] 2740.6
Mass/Charge  
Figure V.b. Mascot result graph of the MALDI-TOF-PSD mass spectrum of the precursor ion 
m/z = 2740.6 with different ion species indicated. 
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